



**Vaccines and Global Health: The Week in Review**  
**14 September 2024 :: Issue 766**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

***Support this knowledge-sharing service:*** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

***Contents [click to move among sections]***

*:: [Milestones, Perspectives](#)*

*:: [WHO](#)*

*:: [Organization Announcements](#)*

*:: [Journal Watch](#)*

*:: [Pre-Print Servers](#)*

*:: [Think Tanks](#)*

## *Milestones, Perspectives*

.....  
.....

### **Gaza – Polio vaccination**

#### **Around 560 000 children vaccinated in first round of polio campaign in Gaza**

*Press release 13 September 2024*

JERUSALEM/AMMAN/GENEVA, 13 SEPTEMBER 2024 - Around 560 000 children under ten years old were vaccinated against polio during the **first round of an emergency vaccination campaign conducted in three phases from 1-12 September 2024 in the Gaza Strip.**

The 12-day campaign provided **novel oral polio vaccine type 2 (nOPV2) to 558 963 children**, following meticulous planning and coordination. This involved the use of an extensive network of teams, vaccinating at selected fixed sites at health facilities and outreach posts. Mobile and transit teams actively reached out to families living in shelter homes, tents, and camps for the displaced, alongside community workers engaging families to raise awareness ahead of and during the campaign. For each phase, an area-specific humanitarian pause of nine hours daily was agreed to ensure the safety of communities and health workers, and enable vaccination efforts.

**“Health and community workers have shown incredible resilience, carrying out this campaign at unprecedented scale and speed under the toughest conditions in Gaza.** Swift action by the Global Polio Eradication Initiative—from the moment the virus was detected to the launch of the vaccination campaign—speaks to the effectiveness of the polio programme. In areas where humanitarian pauses took place, the campaign brought not just vaccines, but moments of calm. As we prepare for the next round in four weeks, we’re hopeful these pauses will hold, because this campaign has clearly shown the world what’s possible when peace is given a chance,” said Dr Richard Peeperkorn, WHO Representative for the occupied Palestinian territory (oPt).

“It was critical this ambitious campaign was carried out quickly, safely and effectively to protect children in the Gaza Strip and neighbouring countries from the life-altering poliovirus,” said Jean Gough, UNICEF Special Representative in the State of Palestine. “The progress made in this first round is encouraging, but the job is far from done. **We are poised to finish the task and call on all involved to ensure we can do so in the next round in four weeks' time, for the sake of children everywhere.**”...

**The original target for the campaign was 640 000 children, estimated in the absence of an accurate survey, which may have been an over-estimate,** as the population continues to move from place to place, and people are fleeing and being killed due to the ongoing hostilities. During the campaign, trained monitoring teams were deployed to oversee vaccination efforts. As next steps, an additional 65 independent monitors are being deployed to cross-check the proportion of children vaccinated across the Gaza Strip to independently assess the level of coverage achieved in the first round. They need safe, unimpeded access so they can visit households, markets, transit points, and health facilities to check children for the prominent purple dye marked on their little finger when they are vaccinated. These efforts will provide an independent measure of the percentage of vaccination coverage achieved and reasons for any unvaccinated children.

**A second round of the campaign will follow, ideally within four weeks, to provide a second dose of nOPV2 to children in Gaza to stop the outbreak and prevent its international spread.**

To repeat this ambitious intervention, reach enough children, and successfully stop further transmission of the poliovirus, WHO, UNICEF and UNRWA are calling on all parties to the conflict to commit to another round of humanitarian pauses, with unimpeded access to children in areas that need special coordination...

.....  
.....

## **Mpox - PHEIC**

### **Multi-country outbreak of mpox, External situation report#36- 14 September 2024**

Edition 36 14 September 2024 | Emergency Situational Updates

KEY FIGURES		
Global – Laboratory confirmed		Reporting period: 1 January 2022 - 31 July 2024
<b>Cases</b> 103 048	<b>Deaths</b> 229	<b>Countries affected</b> 121
Africa – Laboratory confirmed		Reporting period: 1 January 2024 – 8 September 2024 <sup>1</sup>
<b>Cases</b> 5759	<b>Deaths</b> 32	<b>Countries affected</b> 15
Selected countries experiencing rapid increases: all cases (suspected and tested cases) <sup>2</sup>		Reporting period: 1 January 2024 – 8 September 2024
<b>Burundi</b> 1489	<b>Democratic Republic of the Congo</b> 21 835	

### ***Highlights***

- On 14 August 2024, the WHO Director-General declared the resurgence of mpox to be a public health emergency of international concern (PHEIC), requiring a coordinated international response.
- This report focuses on the reporting period 1 January – 8 September 2024, as the latest complete epidemiological week, for the African continent. Global updates will be included once a month.
- The number of suspected and confirmed mpox cases reported in Africa in 2024 continues to increase. The most affected countries currently are the Democratic Republic of the Congo and Burundi.
- Testing coverage in the Democratic Republic of the Congo remains low, due to limited testing capacity, and the number of suspected cases is around five times the number of laboratory-confirmed ones.
- Mpox case fatality ratio in the Democratic Republic of the Congo in 2024 is 0.5% among confirmed cases (25 deaths out of 5160 cases) and 3.3% among suspected cases (717 deaths among 21 835 cases).
- In Africa, the two monkeypox virus (MPXV) clades and their subclades circulate in different geographic areas and affecting different populations, therefore need tailored and locally-adapted outbreak responses.
- Clade Ib, in circulation for approximately one year, has been associated with sustained human-to-human transmission and a rising trend in reported cases in eastern Democratic Republic of the Congo. Clade Ib is also causing an ongoing outbreak in Burundi.
- Although genomic sequencing capacity is limited, clade Ib appears to be the predominant strain in the North and South Kivu provinces of the Democratic Republic of the Congo, Burundi, Rwanda, Kenya, and Uganda, and has been confirmed in imported cases in Sweden and Thailand, one case in each country.

- This report presents an overview of the epidemiological situation in three countries that have national declarations of mpox outbreaks (Democratic Republic of the Congo, Burundi and Central African Republic). Future reports will include overviews from more countries.
- Comprehensive global, continental and national planning to address the mpox situation are underway. This report provides an overview of WHO global mpox response activities.
- This report also includes two brief special focus sections providing updates on laboratory testing for clade Ib MPXV and the current global situation regarding vaccine availability and distribution.
- **WHO has announced on 13 September the prequalification of MVA-BN vaccine, the first vaccine against mpox to be prequalified.**

.....

### **WHO prequalifies the first vaccine against mpox**

13 September 2024 *News release*

The World Health Organization (WHO) has announced **the MVA-BN vaccine as the first vaccine against mpox to be added to its prequalification list...**

**WHO's assessment for prequalification is based on information submitted by the manufacturer, Bavarian Nordic A/S, and review by the European Medicines Agency, the regulatory agency of record for this vaccine.**

"This first prequalification of a vaccine against mpox is an important step in our fight against the disease, both in the context of the current outbreaks in Africa, and in future," said **WHO Director-General Dr Tedros Adhanom Ghebreyesus**. **"We now need urgent scale up in procurement, donations and rollout to ensure equitable access to vaccines where they are needed most,** alongside other public health tools, to prevent infections, stop transmission and save lives."

**The MVA-BN vaccine can be administered in people over 18-years of age as a 2-dose injection given 4 weeks apart. After prior cold storage, the vaccine can be kept at 2–8°C for up to 8 weeks...**

The **WHO Strategic Advisory Group of Experts (SAGE) on Immunization reviewed all available evidence and recommended the use of MVA-BN vaccine in the context of an mpox outbreak for persons at high risk of exposure.** While MVA-BN is currently not licensed for persons under 18 years of age, **this vaccine may be used "off-label" in infants, children and adolescents, and in pregnant and immunocompromised people.** This means vaccine use is recommended in outbreak settings where the benefits of vaccination outweigh the potential risks.

WHO also recommends single-dose use in supply-constrained outbreak situations. WHO emphasizes the need to collect further data on vaccine safety and effectiveness in these circumstances...

.....

### **WHO and partners establish an access and allocation mechanism for mpox vaccines, treatments, tests**

13 September 2024 *News release*

In coordination with Member States, the World Health Organization (WHO) and partners have established an access and allocation mechanism for mpox medical countermeasures including vaccines, treatments and diagnostic tests. The **Access and Allocation Mechanism (AAM) will increase access to these tools for people at highest risk and ensure that the limited supplies are used effectively and equitably.**

This is part of the response to the public health emergency of international concern declared by WHO Director-General Dr Tedros Adhanom Ghebreyesus on 14 August 2024, following an upsurge of mpox in the Democratic Republic of the Congo and neighbouring countries. Fifteen countries in Africa have reported mpox this year. Recommendations issued on the advice of the International Health Regulations Emergency Committee asked States Parties to ensure "equitable access to safe, effective and quality-assured countermeasures for mpox."

"Alongside other public health interventions, vaccines, therapeutics and diagnostics are powerful tools for bringing the mpox outbreaks in Africa under control," said WHO Director-General Dr Tedros Adhanom Ghebreyesus. "The COVID-19 pandemic illustrated the need for international coordination to promote equitable access to these tools so they can be used most effectively where they are most needed. **We urge countries with supplies of vaccines and other products to come forward with donations, to prevent infections, stop transmission and save lives.**"

**The AAM was established as a part of the interim Medical Countermeasures Network (i-MCM-Net).** The i-MCM-Net brings together partners from around the world, including UN and other international agencies, health organizations, civil society organizations, industry and private sector to build an effective ecosystem for the development, manufacturing, allocation and delivery of medical countermeasures. The network was endorsed by WHO Member States as a mechanism to operate in the interim, as negotiations continue towards a pandemic agreement.

**Along with WHO, the AAM for mpox includes members of the i-MCM-Net: the Africa Centres for Disease Control and Prevention, the Coalition for Epidemic Preparedness Innovations, the EU's Health Emergency Preparedness and Response Authority, FIND, Gavi, the PAHO Revolving Fund, UNICEF, Unitaïd and others.**

**Over 3.6 million doses of vaccines have been pledged for the mpox response.** This includes 620 000 doses of the MVA-BN vaccine pledged to affected countries by the European Commission, Austria, Belgium, Croatia, Cyprus, France, Germany, Luxembourg, Malta, Poland, Spain, and the United States of America, as well as vaccine manufacturer Bavarian Nordic. Japan has pledged 3 million doses of the LC16 vaccine, the largest number of doses pledged so far.

The recent surge in mpox cases, coupled with the limited availability of vaccines and other medical countermeasures, underscores the need for a collaborative and transparent process to distribute these critical resources fairly. **The AAM is working to allocate the currently scarce supplies of vaccines and diagnostics for those at the highest risk of infection,** including for vaccinating contacts of confirmed cases, and providing access to point of care diagnostics to countries with ongoing mpox outbreaks so that people who might be suspected cases can systematically be tested and cared for.

**The AAM will operate based on these guiding principles:**

- **Preventing illness and death:** Prioritize vaccination and other tools to interrupt transmission for those at greatest risk to prevent illness and death.
- **Mitigating inequity:** Ensure equitable access to medical countermeasures for all people at risk, irrespective of socio-economic or demographic background.
- **Ensuring transparency and flexibility:** Establish and maintain clear and open communication about allocation decisions and be ready to adapt strategies as new data emerge or situations change.

"WHO and partners are supporting the government of the Democratic Republic of the Congo and other countries to implement an integrated approach to case detection, contact tracing, targeted vaccination, clinical and home care, infection prevention and control, community engagement and mobilization, and

specialized logistical support,” said Dr Mike Ryan, Executive Director of WHO’s Health Emergencies Programme. “The AAM will provide a reliable pipeline of vaccines and other tools in order to ensure the success on the ground in interrupting transmission and reducing suffering.”

.....

### **UNICEF scales up efforts to protect children from mpox outbreak in the Democratic Republic of the Congo**

KINSHASA, 12 September 2024 – As the number of mpox cases continues to rise across the Democratic Republic of the Congo (DRC), **UNICEF is stepping up its support to the government to protect and save the lives of children under 15 years of age who account for about 60 per cent of suspected cases and 80 per cent of deaths this year.**

From the beginning of the year to 31 August 2024, the DRC has recorded more than 21,000 suspected mpox cases, including over 5,000 confirmed cases and 700 deaths...

**Over the past week, UNICEF received the first shipments of the mpox vaccine totalling 215,000 doses.** More shipments are expected to arrive soon. Meanwhile, UNICEF is supporting the vaccine roll-out through related supplies and logistics, and training of health workers in transportation, storage, and administration of vaccines to patients.

Working with the DRC government, WHO, and Africa CDC, **UNICEF is leading on infection prevention and control, risk communication and community engagement, nutrition, mental health and psychological support, and operational research.**

In recent months, UNICEF has enhanced community-based surveillance, training over 200 health workers, 100 hygienists, and 200 community engagement teams. Additionally, 6,000 community workers have been deployed to raise awareness, with more than 30 local radio stations broadcasting public health messages.

**UNICEF has also set up mpox treatment and isolation units in busy health centres,** including Kavumu and Lwiro in the Miti Murhesa health zone, offering free treatment with a capacity of 20 to 30 beds. More than 30 medical kits have been distributed in the health zones of Kavumu, Lwiro, Kamanyola, and Uvira, as well as at Miti Murhesa General Hospital and Bukavu Central Prison. Between May and August 2024, these interventions helped care for over 1,500 patients, over 70 per cent of whom are children under 15.

Community engagement teams have so far reached 46 million people across DRC with mpox messages via mass media, face-to-face engagement, and SMS and digital channels. Upcoming efforts will focus on vaccine efficacy and safety while countering misinformation. UNICEF supports risk communication and community engagement across all 26 provinces.

**UNICEF’s mpox response targets 12 out of DRC’s 26 provinces, with five provinces considered as very high priority\*.** The agency requires a total of \$35 million to reach a total of 2.28 million people, including 1.32 million children, over the next 6 months. The funding gap currently stands at 79 per cent.

Across DRC, more than 25 million people need humanitarian assistance, including almost 15 million children. In the east of the country alone, 7 million people are displaced, making DRC one of the biggest displacement crises globally.

"Many of the people affected by the mpox emergency were already facing multiple deprivations due to armed conflict, displacement and other disease outbreaks," said Dr Sylla. "The mpox response must not overlook pre-existing humanitarian needs, and any measures should serve to reinforce existing efforts."

.....  
.....

## Featured Analysis

### Regulatory Processes for Rare Disease Drugs in the United States and European Union Flexibilities and Collaborative Opportunities

Consensus Study Report 2024 :: 319 pages

National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Processes to Evaluate the Safety and Efficacy of Drugs for Rare Diseases or Conditions in the United States and the European Union; Jeffrey P. Kahn, Carson W. Smith, Tequam L. Worku, and Carolyn K. Shore, Editors

#### *Abstract*

Rare diseases, such as sickle cell disease and thalassemia, affect up to 30 million people in the United States and at least 300 million across the globe. Congress called on the U.S. Food and Drug Administration (FDA) to sponsor a National Academies study on processes for evaluating the safety and efficacy of drugs for rare diseases or conditions in the United States and the European Union. The resulting report provides recommendations for enhancing and promoting rare disease drug development by improving engagement with people affected by a rare disease, advancing regulatory science, and fostering collaboration between FDA and the European Medicines Agency.

#### *Summary*

There are an estimated 7,000 to 10,000 life-threatening and chronically debilitating rare diseases. While each disease affects only a small number of people, together rare diseases affect up to 30 million individuals in the United States, 36 million in the European Union, and at least 300 million across the globe. The impact of rare diseases extends well beyond the affected individual to include family members and caregivers, imposing a significant burden on an estimated 1 billion people globally, when accounting for both people living with a rare disease or condition and their caregivers.

The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) play a critical role in protecting public health by ensuring that drugs to treat rare diseases and conditions are safe and effective. Additionally, the agencies help advance the public health by actively promoting scientific and technological innovation for advancing drug development....

For people living with rare disease and conditions, there is an urgent need to increase the pace and volume of drug development and of regulatory approval processes. Patient groups have expressed frustration with regulatory agencies, raising legitimate questions about how agencies analyze data gathered from small trials and consider patient and caregiver input in regulatory decision making, noting seeming inconsistencies around drug products that are approved by one agency and not the other, and asking how and when FDA applies regulatory flexibilities across its centers and divisions.

The U.S. Congress called on FDA to contract with the National Academies of Sciences, Engineering, and Medicine (National Academies) to conduct a study on processes for evaluating the safety and efficacy of drugs for rare diseases in the United States and the European Union. The statement of task includes: [1] flexibilities and mechanisms available to regulators, [2] the consideration and use of "supplemental data" submitted during the review process, and [3] an assessment of collaborative efforts between the FDA and EMA.



The committee was specifically asked to focus on the regulatory processes for the review and approval of new molecular entities (NMEs) and biologics. As requested by the sponsor, drug repositioning or repurposing, new indications for drugs already approved, N-of-1 or single participant clinical trials, devices, new modalities, and platform technologies were considered outside the scope of this report. While the committee looked at areas for collaboration between the United States and the European Union, recommendations are focused primarily on the United States...

Recommendations in this report seek to enhance strategic engagement of FDA with people living with a rare disease or condition, their caregivers, and patient representatives, especially patient groups that are small and under-resourced, throughout the full continuum of the drug development process; advance regulatory science, including the use of innovative study designs and methods and application of alternative and confirmatory data to inform regulatory decision making for rare disease drug products; and improve collaboration between FDA and EMA...

.....  
.....

## Featured Pre-print Literature

### Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 14 Sep 2024]

*Open Letter* metrics AWAITING PEER REVIEW

### [Estimating the impact of vaccination: lessons learned in the first phase of the Vaccine Impact Modelling Consortium](#)

[version 1; peer review: awaiting peer review]

Katy A M Gaythorpe, Xiang Li, Hannah Clapham, Emily Dansereau, Rich Fitzjohn, Wes Hinsley, Daniel Hogan, Mark Jit, Tewodaj Mengistu, T Alex Perkins, Allison Portnoy, Emilia Vynnycky, Kim Woodruff, Neil M Ferguson, Caroline L Trotter

Peer Reviewers Invited

Funders: Wellcome Trust; Medical Research Council

PUBLISHED 13 Sep 2024

#### *Abstract*

Estimates of the global health impact of immunisation are important for quantifying historical benefits as well as planning future investments and strategy. The Vaccine Impact Modelling Consortium (VIMC) was established in 2016 to provide reliable estimates of the health impact of immunisation.

In this article we examine the consortium in its first five-year phase. We detail how vaccine impact was defined and the methods used to estimate it as well as the technical infrastructure required to underpin robust reproducibility of the outputs. We highlight some of the applications of estimates to date, how these were communicated and what their effect were. Finally, we explore some of the lessons learnt and remaining challenges for estimating the impact of vaccines and forming effective modelling consortia then discuss how this may be addressed in the second phase of VIMC.

Modelled estimates are not a replacement for surveillance; however, they can examine theoretical counterfactuals and highlight data gaps to complement other activities. VIMC has implemented strategies to produce robust, standardised estimates of immunisation impact. But through the first phase of the consortium, critical lessons have been learnt both on the technical infrastructure and the effective engagement with modellers and stakeholders.

To be successful, a productive dialogue with estimate consumers, producers and stakeholders needs to be underpinned by a rigorous and transparent analytical framework as well as an approach for building expertise in the short and long term.



.....  
.....

## Polio – PHEIC

### Polio this week as of 04 September 2024 - GPEI

:: In Gaza, the first round of the vaccination response is completing this week, as teams continue to vaccinate children against the recently-detected strain. More on Gaza, including daily updates from the campaign, are available at the following link (please click on occupied Palestinian territory

#### ***Summary of new polioviruses this week, cases and positive environmental isolates:***

- Pakistan: one WPV1 case and 15 positive environmental samples
- Algeria: 1 cVDPV2-positive environmental sample
- DR Congo: one cVDPV2 case
- Ghana: 1 cVDPV2-positive environmental sample

.....  
.....

#### ***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....  
.....

#### **WHO & Regional Offices** [to 14 Sep 2024]

<https://www.who.int/news>

*Selected News/Announcements/Statements*

13 September 2024 *News release*

**[Around 560 000 children vaccinated in first round of polio campaign in Gaza](#)**

13 September 2024 *News release*

**[WHO updates influenza care guidelines, includes recommendations for viruses with pandemic potential](#)**

13 September 2024 *News release*

**[WHO and partners establish an access and allocation mechanism for mpox vaccines, treatments, tests](#)**

13 September 2024 *News release*

**[WHO prequalifies the first vaccine against mpox](#)**

12 September 2024 *News release*

**[WHO analysis highlights vast unmet rehabilitation needs in Gaza](#)**

9 September 2024 *News release*

**[High-level mission to Sudan reaffirms WHO commitment, calls for urgent action to address and end the extreme health and humanitarian crisis](#)**

.....

## **WHO Regional Offices**

*Selected Press Releases, Announcements*

### **WHO African Region**

:: [WHO expands field response capacity to curb mpox in Democratic Republic of the Congo](#)

13 September 2024

### **WHO Region of the Americas PAHO**

:: 10 Sep 2024

[PAHO publishes update on Oropouche fever in the Americas](#)

Washington, DC, September 10, 2024 (PAHO) – The Pan American Health Organization (PAHO) recently issued an update on Oropouche fever (OROV) in the Americas, urging countries to strengthen surveillance, report any unusual events, and reinforce vector prevention and control measures. In 2024, the virus has been detected in areas where...

### **WHO South-East Asia Region SEARO**

*No new digest content identified.*

### **WHO European Region EURO**

*No new digest content identified.*

### **WHO Eastern Mediterranean Region EMRO**

:: 12 September 2024 *Statement*

[Statement – Renewed focus on health critical as Ukraine approaches third winter amid full-scale war](#)

### **WHO Western Pacific Region**

*No new digest content identified.*

.....

## **WHO - Emergency situation reports**

*Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.*

[Multi-country outbreak of mpox, External situation report#36- 14 September 2024](#)

.....

## **Disease Outbreak News (DONs)**

*Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.*

*No new digest content identified.*

.....

## **Weekly Epidemiological Record**

<https://www.who.int/publications/journals/weekly-epidemiological-record>

**Vol. 99, No. 37, pp. 497–522 13 September 2024**

PDF: <https://iris.who.int/bitstream/handle/10665/378893/WER9937-eng-fre.pdf>

:: WHO's Health Emergencies Programme: acute emergencies monthly summary – August 2024  
:: Global leprosy (Hansen disease) update, 2023: Elimination of leprosy disease is possible – Time to act!

.....

## **New WHO Publications**

<https://www.who.int/publications/i>

*Selected*

12 September 2024

**[Clinical practice guidelines for influenza](#)**

10 September 2024

**[Report of the ninth meeting of the WHO Strategic and Technical Advisory Group of Experts for Maternal,...](#)**

10 September 2024

**[Refugee and migrant health system review: challenges and opportunities for long-term health system strengthening in Uganda](#)**

10 September 2024

**[Governance of the private sector in fragile, conflict-affected and vulnerable settings](#)**

*Overview*

Within fragile, conflict-affected and vulnerable settings (FCVs), health system governance arrangements have evolved in response to conflict, creating a complex foundation for service provision. Service provision is often pluralist in nature comprising state actors, foreign operators and local private-not-for-profit and for-profit providers. This brief focuses on this wide terrain of governance interaction and the effects this has on health service delivery and access for conflict affected populations. It outlines three strategies for policy response and associated tools. Country cases reviewed for the brief have focused on well-known FCVs and those suffering from a confluence of crises related to security, humanitarian, political, and economic factors.

9 September 2024

**[Health practitioner regulation: Design, reform and implementation guidance](#)**

9 September 2024

**[Implementation toolkit for accessible telehealth services](#)**

9 September 2024

**[WHO consolidated guidelines on tuberculosis Module 1: prevention - tuberculosis preventive treatment,...](#)**

9 September 2024

**[WHO operational handbook on tuberculosis Module 1: prevention - tuberculosis preventive treatment, second...](#)**

8 September 2024

**[WHO clinical consortium on healthy ageing 2023](#)**

.....

.....

## USA – HHS, FDA, CDC

### HHS

*News*

#### [HHS Finalizes Rule on Research Misconduct to Foster Research Integrity](#)

September 12, 2024 News Release

### FDA

*Press Announcements*

*No new digest content identified.*

### FDA VRBPAC

*Advisory Committee Calendar*

#### [Vaccines and Related Biological Products Advisory Committee September 20, 2024 Meeting Announcement - 09/20/2024](#)

### CDC/ACIP [U.S.] [to 14 Sep 2024]

<http://www.cdc.gov/media/index.html>

*Latest News*

*No new digest content identified.*

### ACIP Meetings

*Next ACIP Meeting*

October 23-24, 2024

### MMWR Weekly

<https://www.cdc.gov/mmwr/index2023.html>

#### **September 12, 2024 / No. 36**

[PDF of this issue](#)

- [Progress Toward Achieving National HIV/AIDS Strategy Goals for Quality of Life Among Persons Aged ≥50 Years with Diagnosed HIV — Medical Monitoring Project, United States, 2017–2023](#)
- [Progress Toward Poliomyelitis Eradication — Pakistan, January 2023–June 2024](#)
- [Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024](#)
- [Use of Haemophilus influenzae Type b–Containing Vaccines Among American Indian and Alaska Native Infants: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2024](#)

.....

.....

## Europe

### European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

*News & Press Releases*

*No new digest content identified.*

### European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

*News/Updates/Reports/Publications [Selected]*

## **Epidemiological update – Week 36/2024: Mpox due to monkeypox virus clade I**

9 Sep 2024

*Surveillance and monitoring*

### **Communicable disease threats report, 7- 13 September 2024, week 37**

13 Sep 2024

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 7- 13 September 2024 and includes updates on respiratory virus epidemiology in the EU/EEA, West Nile virus, mpox, measles, Avian influenza, dengue and mass gathering monitoring for the Olympic and Paralympic Games.

*Surveillance and monitoring*

### **Monthly updates: 2024 West Nile virus transmission season**

13 Sep 2024

Monthly updates with the latest reports on West Nile virus cases in Europe.

.....  
.....

**Africa CDC** [to 14 Sep 2024]

<https://africacdc.org/>

*Press Releases, Statements [Selected]*

### **Africa CDC Postpones CPHIA 2024 Conference**

13 September 2024

*Press Releases*

### **Africa CDC Welcomes Pandemic Fund's Statement: Urgent Call for Speed, Agility, and Impactful Action in Africa's Mpox Response**

11 September 2024

*Media Advisory*

### **Special Press Briefing on the Mpox Outbreak and other Health Emergencies in Africa**

10 September 2024

.....  
.....

**China CDC**

<http://www.chinacdc.cn/en/>

**National Health Commission of the People's Republic of China** [to 14 Sep 2024]

<http://en.nhc.gov.cn/>

*News*

*No new digest content identified.*

**National Medical Products Administration – PRC** [to 14 Sep 2024]

<http://english.nmpa.gov.cn/>

*News*

*No new digest content identified.*

**China CDC**

**CCDC Weekly Reports: Current Volume (6)**

**2024-09-13 / No. 37**

[View PDF of this issue](#)

- [Methods and Applications: Mapping the Characteristics of Respiratory Infectious Disease Epidemics in China Based on the Baidu Index from November 2022 to January 2023](#)
- [Methods and Applications: Establishment of a Lateral Flow Dipstick Detection Method for Influenza A Virus Based on CRISPR/Cas12a System](#)
- [Methods and Applications: Development and Diagnosis Performance of IgM-Based Rapid Antigen Test for Early Detection of SARS-CoV-2 Infection in a Large Cohort of Suspected COVID-19 Cases — USA, Poland, and Sweden, 2021–2022](#)

.....  
.....

### ***Contents [click to move among sections]***

[:: Milestones, Perspectives](#)

[:: WHO](#)

[:: Organization Announcements](#)

[:: Journal Watch](#)

[:: Pre-Print Servers](#)

.....  
.....

### ***Organization Announcements***

**Paul G. Allen Frontiers Group** [to 14 Sep 2024]

<https://alleninstitute.org/news-press/>

*News*

**[The Paul G. Allen Frontiers Group announces Allen Discovery Center for Neurobiology in Changing Environments](#)**

09.10.2024

New research center at UC San Diego's Scripps Institution of Oceanography will study how climate change affects marine life

**BMGF - Gates Foundation** [to 14 Sep 2024]

<https://www.gatesfoundation.org/ideas/media-center>

*Press Releases & Statements*

*No new digest content identified.*

**Bill & Melinda Gates Medical Research Institute** [to 14 Sep 2024]

<https://www.gatesmri.org/news>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*

*News: Articles and Publications*

*No new digest content identified.*

**CARB-X** [to 14 Sep 2024]

<https://carb-x.org/>

*News*

*No new digest content identified.*

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 14 Sep 2024]

<http://cepi.net/>

*CEPI News*

*No new digest content identified.*

**CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to 14 Sep 2024]

<https://cioms.ch/>

*News; Publications; Events*

**[Chinese translation now available](#)**

The Chinese translation of the 2024 report *Real-world data and real-world evidence in regulatory decision making* is now available [here](#)

**DARPA – Defense Advanced Research Projects Agency [U.S.]** [to 14 Sep 2024]

<https://www.darpa.mil/news>

*News*

*No new digest content identified.*

**Duke Global Health Innovation Center** [to 14 Sep 2024]

<https://dukeghic.org/>

*News*

*No new digest content identified.*

**EDCTP** [to 14 Sep 2024]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

*News*

*No new digest content identified.*

**Emory Vaccine Center** [to 14 Sep 2024]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

**European Vaccine Initiative** [to 14 Sep 2024]

<http://www.euvaccine.eu/>

*Latest News, Events*

*No new digest content identified.*



**Evidence Aid** [to 14 Sep 2024]

*Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.*

<http://www.evidenceaid.org/>

*Resources [Selected]*

**[Availability and Suitability of Digital Health Tools in Africa for Pandemic Control: Scoping Review and Cluster Analysis](#)**

Added September 12, 2024

**Fondation Merieux** [to 14 Sep 2024]

<http://www.fondation-merieux.org/>

*News, Events*

*No new digest content identified.*

**Gavi** [to 14 Sep 2024]

<https://www.gavi.org/>

*Press Releases*

*No new digest content identified.*

**GE2P2 Global Foundation** [to 14 Sep 2024]

[www.ge2p2.org](http://www.ge2p2.org)

*News/Analysis/Publications-Digests/Statements*

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – June 2024](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 10 Sep 2024 – Issue 23](#)

**GHIT Fund** [to 14 Sep 2024]

<https://www.ghitfund.org/newsroom/press>

*Press Releases*

*No new digest content identified.*

**Global Fund** [to 14 Sep 2024]

<https://www.theglobalfund.org/en/news/>

*News Releases*

*No new digest content identified.*

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 14 Sep 2024]

<https://www.glopid-r.org/news/>

*News*

*No new digest content identified.*

**Hilleman Laboratories** [to 14 Sep 2024]

<http://www.hilleman-labs.org/>  
*News & Insights*  
*No new digest content identified.*

**HHMI - Howard Hughes Medical Institute** [to 14 Sep 2024]

<https://www.hhmi.org/news>  
*Press Room*  
*No new digest content identified.*

**Human Immunome Project [nee Human Vaccines Project]** [to 14 Sep 2024]

<https://www.humanimmunomeproject.org/>  
*News*  
*No new digest content identified.*

**IAVI** [to 14 Sep 2024]

<https://www.iavi.org/>  
*News, Features*  
*No new digest content identified.*

**INSERM** [to 14 Sep 2024]

<https://www.inserm.fr/en/home/>  
*Press Releases*  
*No new digest content identified.*

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>  
*Selected Statements, Press Releases, Research*  
*No new digest content identified.*

**ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use]** [to 14 Sep 2024]

<https://www.ich.org/>  
*News/Pubs/Press Releases [Selective]*  
*No new digest content identified.*

**ICRC** [to 14 Sep 2024]

<https://www.icrc.org/en/whats-new>  
*What's New [Selected]*  
*No new digest content identified.*

**IFFIm**

<http://www.iffim.org/>  
*Press Releases/Announcements*  
*No new digest content identified.*

**IFRC** [to 14 Sep 2024]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Press Releases [Selected]*

*No new digest content identified.*

**Institut Pasteur** [to 14 Sep 2024]

<https://www.pasteur.fr/en/press-area>

*Press Documents*

*No new digest content identified.*

**ISC / International Science Council** [to 14 Sep 2024]

<https://council.science/current/>

*Latest Updates*

*blog*

13 September 2024 min read

**[The United Nations Secretary-General's Scientific Advisory Board \(SAB\): Mobilizing science for a sustainable future](#)**

At the inaugural retreat of the UN Secretary-General's Scientific Advisory Board, the ISC called for further engagement of the global scientific community in support of evidence-informed decision-making.

*blog*

12 September 2024

**[Rebuilding trust in science: Challenges and responsibilities in a polarized world](#)**

The workshop on "Trust in Science-Informed Public Policy" is being held in Ispra, Italy, from 12-13 September 2024 in partnership with the European Commission's Joint Research Centre

**International Union of Immunological Societies (IUIS)**

<https://iuis.org/>

*News/Events [Selected]*

*No new digest content identified.*

**IVAC** [to 14 Sep 2024]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

*No new digest content identified.*

**IVI** [to 14 Sep 2024]

<http://www.ivi.int/>

*IVI News & Announcements*

*No new digest content identified.*

**Johns Hopkins Center for Health Security** [to 14 Sep 2024]

<https://centerforhealthsecurity.org/newsroom>

*Center News [Selected]*  
*No new digest content identified.*

**MSF/Médecins Sans Frontières** [to 14 Sep 2024]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*Sudan*

**[Cholera is Sudan's latest peril](#)**

Project Update 11 Sep 2024

**National Academy of Medicine** - USA [to 14 Sep 2024]

<https://nam.edu/programs/>

*News [Selected]*

*No new digest content identified.*

**National Academies-Sciences-Engineering-Medicine [NASEM]**- USA [to 14 Sep 2024]

<https://www.nationalacademies.org/newsroom?>

*News*

**[To Increase Pace and Volume of Drug Approvals for Rare Diseases, Report Recommends FDA Enhance Information Sharing, Improve Collaboration](#)**

*News Release | September 12, 2024*

WASHINGTON — The Food and Drug Administration should enhance information sharing, advance the regulatory science needed to evaluate rare disease drugs, improve engagement with people with rare diseases and their caregivers, and enhance collaboration with the European Medicines Agency to increase the pace and volume at which drugs to treat rare diseases and conditions are developed and approved, says a [new report](#) from the National Academies of Sciences, Engineering, and Medicine.

**National Vaccine Program Office** - U.S. HHS [to 14 Sep 2024]

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

*No new digest content identified.*

**NIH** [to 14 Sep 2024]

<http://www.nih.gov/>

Friday, September 13, 2024

**[NIH awards establish pandemic preparedness research network](#)**

*Scientists will work on high-priority pathogens most likely to threaten human health.*

The National Institutes of Health (NIH) has established a pandemic preparedness research network to conduct research on high-priority pathogens most likely to threaten human health with the goal of developing effective vaccines and monoclonal antibodies. Currently, many of the diseases caused by these pathogens have no available vaccines or therapeutics, and investing in this research is key to preparing for potential public health crises—both in the United States and around the world. NIH's National Institute of Allergy and Infectious Diseases (NIAID) expects to commit approximately \$100 million per year to fund the program, pending the availability of funds.

The [Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness network](#)—called ReVAMPP—will focus its research efforts on “prototype pathogens,” representative

pathogens from virus families known to infect humans, and high-priority pathogens that have the potential to cause deadly diseases...

The ReVAMPP network will focus on viruses from families within:

- Crimean Congo Hemorrhagic Fever, and [Lassa Fever\(link is external\)](#)
- The Flaviviridae family, which includes viruses that cause [dengue](#) and [yellow fever\(link is external\)](#)
- The Paramyxoviridae family, which includes viruses that cause [measles\(link is external\)](#), [mumps\(link is external\)](#), and Nipah-induced encephalitis
- The Picornaviridae family, which includes viruses that cause poliomyelitis, [foot-and-mouth disease\(link is external\)](#), and myocarditis
- The Togaviridae family, which includes viruses that induce [Chikungunya\(link is external\)](#) virus-induced arthralgia or encephalitis and Venezuelan equine encephalitis...

Tuesday, September 10, 2024

### **[Emergency department screening more than doubles detection of syphilis cases](#)**

*NIH-supported study shows potential of strategy to reach people with and without symptoms.*

**PATH** [to 14 Sep 2024]

<https://www.path.org/media-center/>

*Newsroom*

### **[PATH appoints Dr. Bilal Mateen as inaugural Chief AI Officer](#)**

September 9, 2024 by PATH

PATH is pleased to announce the appointment of Bilal Mateen as its Chief AI Officer. In this newly created role, Mateen will lead PATH's efforts to harness the power of artificial intelligence (AI) to accelerate progress toward a world where everyone has the opportunity to live a healthy life.

**Sabin Vaccine Institute** [to 14 Sep 2024]

<https://www.sabin.org/press/>

*Latest News & Press Releases*

*No new digest content identified.*

**UNAIDS** [to 14 Sep 2024]

<http://www.unaids.org/en>

*News, Stories, Updates*

### **[Interactive health and HIV game app reaches more than 300 000 young people in Côte d'Ivoire](#)**

09 September 2024

**UNICEF** [to 14 Sep 2024]

<https://www.unicef.org/media/press-releases>

*Latest press releases, news notes and statements*

*Press release 13 September 2024*

### **[Around 560 000 children vaccinated in first round of polio campaign in Gaza](#)**

*Press release 12 September 2024*

### **[UNICEF responding to severe flooding in West and Central Africa affecting 4 million people](#)**

*Press release 12 September 2024*

**UNICEF scales up efforts to protect children from mpox outbreak in the Democratic Republic of the Congo**

**Unitaid** [to 14 Sep 2024]

<https://unitaid.org/>

*Featured News*

13 September 2024

**Unitaid renews call for clear access strategy after positive results from Gilead's PURPOSE 2 lenacapavir trial**

12 September 2024

**Unitaid seeks bold ideas in new call for proposals to improve medical oxygen access in resource-limited settings**

**Vaccine Equity Cooperative [nee Initiative]** [to 14 Sep 2024]

<https://vaccineequitycooperative.org/news/>

*News*

*No new digest content identified.*

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 14 Sep 2024]

<https://www.vaccineacceptance.org/>

*Announcements, Blog*

*No new digest content identified.*

**Vaccine Confidence Project** [to 14 Sep 2024]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

*No new digest content identified.*

**Vaccine Education Center – Children's Hospital of Philadelphia** [to 14 Sep 2024]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

*No new digest content identified.*

**Wellcome Trust** [to 14 Sep 2024]

<https://wellcome.org/news/all>

*News. Opinion, Reports*

*No new digest content identified.*

**The Wistar Institute** [to 14 Sep 2024]

<https://www.wistar.org/news/press-releases>

*Press Releases*

*No new digest content identified.*

**World Bank** [to 14 Sep 2024]

<http://www.worldbank.org/en/news/all>

*All News [Selected]*

### **Investing in Healthy Longevity Could Save 150 Million Lives**

WASHINGTON, Sept. 12, 2024 – By 2050, one in three people will be over 60 years old. With bold action to promote healthy longevity, developing countries could save 150 million lives and extend millions more, according to a new World Bank report. Saved health care costs, healthier lifestyles, increased workforce productivity, and lower public expenditure on social services would also generate enormous economic value.

The report, “Unlocking the Power of Healthy Longevity: Demographic Change, Non-communicable Diseases and Human Capital,” lays out strategies for governments that can improve health, reduce poverty, address gender inequity, and enhance productivity in low- and middle-income countries. Healthy longevity means the state of good physical, cognitive, and social functioning throughout a person’s lifespan.

Non-communicable diseases (NCDs)—such as diabetes, respiratory diseases, heart diseases, and cancers—already account for more than 70% of all deaths and a significant portion of disease and disability in low- and middle-income countries. These also intersect with climate stress and pandemic vulnerability. The poorest and most vulnerable people are most susceptible to NCDs because of higher rates of smoking, alcohol use, and obesity and lower quality of health care, and are least able to afford treatment and cope with income loss...

### **Unlocking the Power of Healthy Longevity: Demographic Change, Non-communicable Diseases, and Human Capital**

*Download Full Report | Replay Launch Event*

Date: September 12, 2024 Type: Publication

#### *Synopsis*

:: Healthy longevity means the state of good physical, cognitive, and social functioning throughout a person's lifespan.

:: There's an opportunity to leverage an aging population for health, societal, and economic gains by investing in health and wellbeing throughout people's lives.

:: Investing in healthy longevity could save 150 million lives in low- and middle income countries and extend millions more by 2050, generating significant economic benefit.

**WFPHA: World Federation of Public Health Associations** [to 14 Sep 2024]

<https://www.wfpfa.org/>

*Blog, Events*

*No new digest announcements identified.*

**World Medical Association [WMA]** [to 14 Sep 2024]

<https://www.wma.net/news-press/press-releases/>

*Press Releases*

*No new digest announcements identified.*

**World Organisation for Animal Health [OIE]** [to 14 Sep 2024]

<https://www.oie.int/>

*Press Releases, Statements*

*No new digest announcements identified.*

.....



.....

**ARM [Alliance for Regenerative Medicine]** [to 14 Sep 2024]

<https://alliancerm.org/press-releases/>

*Selected Press Releases*

*No new digest content identified.*

**BIO** [to 14 Sep 2024]

<https://www.bio.org/press-releases>

*Press Releases*

*No new digest announcements identified.*

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 14 Sep 2024]

<http://www.dcvmn.org/>

*News; Upcoming events*

**[ANNUAL GENERAL MEETING 2024](#)**

October 16 - 18, 2024 São Paulo, Brazil

**ICBA – International Council of Biotechnology Associations** [to 14 Sep 2024]

<https://internationalbiotech.org/news/>

*News*

*No new digest announcements identified.*

**IFPMA** [to 14 Sep 2024]

<https://ifpma.org/>

*News, Statements [Selected]*

*Press release 12 September 2024*

**[Only an urgent shift towards prevention-based healthcare can secure economic stability for EU health systems, experts say](#)**

As Governments of EU Member States present their medium-term fiscal structural plans on 20 September, a [new report](#) developed by The European House – Ambrosetti, supported by IFPMA and Vaccines Europe, notes that embedding preventative healthcare – in particular immunisation – into EU Member States’ fiscal policies is paramount to ensure the economic sustainability of healthcare, social care, and welfare systems.

*Statement 9 September 2024*

**[Eleventh meeting of the Intergovernmental Negotiating Body \(INB\)](#)**

On 9 September 2024, IFPMA delivered a statement at the eleventh meeting of the Intergovernmental Negotiating Body (INB) in Geneva, Switzerland.

**International Alliance of Patients’ Organizations – IAPO** [to 14 Sep 2024]

<https://www.iapo.org.uk/news>

*Press and media [Selected]*

*No new digest announcements identified.*

**International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

*No new digest announcements identified.*

**PhRMA** [to 14 Sep 2024]

<http://www.phrma.org/>

*Press Releases*

*No new digest announcements identified.*

.....

.....

## ***Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements***

### **AstraZeneca**

*Press Releases - No new digest announcements identified.*

### **Bavarian Nordic**

*Latest News*

#### **Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine**

*:: First mpox vaccine to obtain prequalification by the WHO*

*:: Approval will help accelerate access to the vaccine for all African countries*

COPENHAGEN, Denmark, September 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that the Company has obtained prequalification from the World Health Organization (WHO) for IMVANEX® (MVA-BN®) as the first mpox vaccine to be added to the WHO prequalification list.

MVA-BN is indicated for active immunization against smallpox, mpox, and related orthopoxvirus infections and disease in all adults 18 years of age and older. According to recommendations from the WHO, MVA-BN may however be used “off-label” in infants, children and adolescents, and in pregnant and immunocompromised people in outbreak settings where the benefits of vaccination outweigh the potential risks[1].

A prequalification or secondary, an emergency use listing is a prerequisite for governments and organizations like Gavi, UNICEF and others to procure and distribute vaccines in African countries, and while the WHO’s intent was to evaluate mpox vaccines for an emergency use listing, the agency has assessed that MVA-BN meets the criteria for a full prequalification. This assessment is based on information submitted by Bavarian Nordic, including certifications, assessment reports and positive opinions issued by the European Medicines Agency (EMA), which is the regulatory agency of record for this vaccine.

Earlier this week, MVA-BN also received a provisional consent from New Zealand Medicines and Medical Devices Safety Authority, Medsafe and a full approval from the Mexican Federal Committee for Protection from Sanitary Risks, COFEPRIS...

September 12, 2024

#### **Bavarian Nordic Provides Update on the Mpox Vaccine Supply Situation**

### **Bharat Biotech**

*Press Releases*

#### **Bharat Biotech Announces Collaboration with Alopexx for the Development and Commercialization of Broad-Spectrum Anti-Microbial Vaccine AV0328**

*Strategic Collaboration Aims to Accelerate Global Access to Potentially Life-Saving Vaccine*

Hyderabad, India, 11th September 2024 – Bharat Biotech, today announced a collaboration with Alopexx, Inc., for the co-development and commercialization of Alopexx's proprietary broad-spectrum anti-microbial vaccine, AV0328, in India and other low income and lower middle-income countries.

As part of the collaboration, the companies will co-develop and commercialize AV0328, a synthetic vaccine targeting poly N-acetyl glucosamine (PNAG), in India and other licensed territories. Alopexx would be entitled to a one-time upfront payment and milestone payments, as well as royalties on future sales of AV0328 in the licensed territories...

#### **BioCubaFarma – Cuba**

Ultimas Noticias - No new digest announcements identified

#### **Biological E**

News - No new digest announcements identified

#### **BioNTech**

Press Releases - No new digest announcements identified

#### **Boehringer**

Press Releases - No new digest announcements identified

#### **CanSinoBIO**

News - Website not responding at inquiry

#### **CIGB**

Latest News - No new digest announcements identified.

#### **Cinnagen**

Recent News - No new digest announcements identified.

#### **Clover Biopharmaceuticals – China**

News - No new digest announcements identified.

#### **Curevac**

News

September 13, 2024

#### **[CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress](#)**

- Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy
- 84% of immune responses were de novo, observed in patients without pre-existing T-cell activity against encoded cancer antigens
- CVGBM was generally well tolerated up to the highest tested dose level of 100 µg with no dose-limiting toxicities
- Most common adverse events were mild to moderate systemic reactions such as headache, fever and chills, which resolved within 1–2 days post injection
- 100 µg was selected as the recommended dose for the dose expansion phase, which recently started enrollment

September 12, 2024

#### **[CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program](#)**

## **Gamaleya National Center/Sputnik**

*Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]*  
*<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]*

## **GSK**

*Press releases for media*

12 September 2024

### **[GSK announces positive headline data from phase II seasonal influenza mRNA vaccine programme](#)**

Data support progression to phase III clinical trials.

11 September 2024

### **[GSK provides update on phase I/II therapeutic herpes simplex virus \(HSV\) vaccine trial](#)**

Results show that GSK3943104 did not meet the study's primary efficacy objective.

## **EuBiologics, S Korea**

*News - No new digest announcements identified.*

## **IMBCAMS, China**

*Home - Website not responding at inquiry.*

## **Janssen/JNJ**

*Press Releases - No new digest announcements identified.*

## **Merck**

*News releases*

### **[Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males](#)**

September 11, 2024

Merck today announced positive top-line results from its pivotal Phase 3 trial (V503-064) evaluating the company's 9-valent Human Papillomavirus (HPV) vaccine, GARDASIL® 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in Japanese males ages 16 to 26 years. The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9 reduced the combined incidence of anogenital persistent infection caused by 9 types of HPV compared with a placebo...

## **Moderna**

*Press Releases*

### **[Moderna's Canadian Manufacturing Facility Receives Drug Establishment License From Health Canada](#)**

September 9, 2024

*Milestone marks a significant step toward producing mRNA vaccines in Canada by 2025*

## **Nanogen**

*News - No new digest announcements identified*

## **Novartis**

*News - No new digest announcements identified.*

## **Novavax**

*Press Releases*

Sep 13, 2024

COVID-19

## **Novavax 2024-2025 Formula COVID-19 Vaccine Available at Major Pharmacies Across the U.S.**

### **Pfizer**

Recent Press Releases - No new digest announcements identified.

### **R-Pharm**

<https://rpharm-us.com/index.php>

[No news or media page identified]

### **Sanofi Pasteur**

Press Releases - No new digest announcements identified

### **Serum Institute of India**

NEWS & ANNOUNCEMENTS - No new digest announcements identified

### **Sinopharm/WIBPBIBP**

News - No new digest announcements identified

### **Sinovac**

Press Releases - No new digest announcements identified.

### **SK Biosciences**

Press Releases - No new digest announcements identified.

### **Takeda**

Newsroom - No new digest announcements identified.

### **Valneva**

Press Releases - No new digest announcements identified.

### **Vector State Research Centre of Virology and Biotechnology**

Home - [Website not responding [404 error]

### **WestVac Biopharma**

Media - No new digest announcements identified.

### **Zhifei Longcom, China**

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]

.....  
.....

### ***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....

.....

### ***Journal Watch***

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

### **AJOB Empirical Bioethics**

Volume 15, 2023 Issue 3

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

### **AMA Journal of Ethics**

Volume 26, Number 9: E665-744

<https://journalofethics.ama-assn.org/issue/nonhuman-animal-research>

#### ***Nonhuman Animal Research***

Nonhuman animals have long been and continue to be routinely used in biomedical and behavioral research to promote human health. When SARS-CoV2 infections triggered a race to develop and scale global access to vaccines in 2019, two key innovations happened to the supply chain of nonhuman animals created, raised, and used for science: (1) experiments and trials regarded as essential were prioritized and (2) governments and researchers shortened vaccine production timelines. Clinical and public health urgency concentrated and acutely focused demand for live mammals—especially ferrets, guinea pigs, hamsters, mice, nonhuman primates, pigs, and rats—in ways that also intensified demand for efficient protocol designs and streamlined methods of human vaccine research and development. Reasonable people can still disagree about when, why, and how nonhuman animals should be sacrificed for human health, but we now know that human health endeavors, specifically vaccine development, flourish even when we sanction fewer nonhuman animals' cultivation and deaths for science. This theme issue investigates what this revelation from the pandemic means from clinical, ethical, legal, and policy standpoints for the future of human-centered research.

### **American Journal of Human Genetics**

Sep 05, 2024 Volume 111 Issue 9 p1797-2070

<https://www.cell.com/ajhg/current>

#### ***This Month in The Journal***

Alyson B. Barnes, Kylee L. Spencer

Proteogenomics draws on the fields of genomics, transcriptomics, and proteomics to discern how genetic variation influences the set of proteins produced by a cell with the goal of elucidating how this relates to disease risk. Although colocalization approaches can be used to identify variants that are tied to both splicing and disease, the limitations of short-read RNA sequencing have often prevented determining which protein isoform or group of isoforms specifically mediates risk. In this issue, Abood et al.

### **American Journal of Infection Control**

September 2024 Volume 52 Issue 9 p985-1104  
<http://www.ajicjournal.org/current>  
[Reviewed earlier]

### **American Journal of Preventive Medicine**

September 2024 Volume 67 Issue 3 p319-476  
<https://www.ajpmonline.org/current>  
[Reviewed earlier]

### **American Journal of Public Health**

October 2024 114(109)  
<http://ajph.aphapublications.org/toc/ajph/current>  
[Reviewed earlier]

### **American Journal of Tropical Medicine and Hygiene**

Volume 111 (2024): Issue 3 (Sep 2024)  
<https://www.ajtmh.org/view/journals/tpmd/111/3/tpmd.111.issue-3.xml>  
[Reviewed earlier]

### **Annals of Internal Medicine**

August 2024 Volume 177, Issue 8  
<https://www.acpjournals.org/toc/aim/current>  
[Reviewed earlier]

### **Artificial Intelligence – An International Journal**

Volume 334 September 2024  
<https://www.sciencedirect.com/journal/artificial-intelligence/vol/334/suppl/C>  
[Reviewed earlier]

### **BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>  
(Accessed 14 Sep 2024)  
[No new digest content identified]

### **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>  
(Accessed 14 Sep 2024)

#### **[Vaccination governance in protracted conflict settings: the case of northwest Syria](#)**

*Effective vaccination governance in conflict-affected regions poses unique challenges. This study evaluates the governance of vaccination programs in northwest Syria, focusing on effectiveness, efficiency, inc...*

Authors: Ronja Kitlope Baatz, Abdulkarim Ekzayez, Yasser Najib, Munzer Alkhalil, Mohammad Salem, Mohammed Ayman Alshiekh and Preeti Patel

Citation: BMC Health Services Research 2024 24:1056

Content type: Research Published on: 12 September 2024



## **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 14 Sep 2024)

### **Coronavirus disease-19 vaccine uptake, willingness for vaccination, and associated Factors among chronic follow patients attending in the two comprehensive specialized hospitals of Bahir Dar, Ethiopia**

*Even though the disease has spread throughout the world, with millions killed, global COVID-19 vaccination coverage remains low, particularly in developing countries. However, epidemiological data is lacking i...*

Authors: Dessie Tegegne, Mulu Kebede, Henok Biresaw, Astewle Andargie, Mengistu Ewunetu and Getenet Dessie

Citation: BMC Infectious Diseases 2024 24:976

Content type: Research Published on: 13 September 2024

### **Immunization status and factors influencing hepatitis B vaccination of preterm infants in three provinces of China, 2019 to 2021**

*Premature infants have less physiologic reserve and often delayed vaccination compared to full-term infants. The birth dose of hepatitis B vaccine (HepB-BD) is an essential measure to achieve the goal of "zero..."*

Authors: Li-fang Huang, Ao-di Huang, Xue Zhang, Lin Tang, Jing An, Jun Li, Hui Zheng, Zun-dong Yin and Fu-zhen Wang

Citation: BMC Infectious Diseases 2024 24:951

Content type: Research Published on: 10 September 2024

## **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 14 Sep 2024)

[No new digest content identified]

## **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 14 Sep 2024)

[No new digest content identified]

## **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 14 Sep 2024)

[No new digest content identified]

## **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 14 Sep 2024)

### **Level of hesitation of parents about childhood vaccines and affecting factors: a cross-sectional study in Turkey**

*Hesitancy rates for childhood vaccines are increasing on a global scale. It was reported in previous studies that many factors affect vaccine hesitancy. The present study was designed to determine the prevalen...*

Authors: Vasfiye BAYRAM DEĞER and Gülhan YİĞİTALP

Citation: BMC Public Health 2024 24:2494

Content type: Research Published on: 13 September 2024

**The influence of the perception, attitude, and level of trust on the uptake of COVID-19 vaccinations among pregnant women attending antenatal care clinic in mbeya urban, Tanzania**

*Coronavirus Disease 2019 (COVID–19) has been associated with adverse effects and death among people with low immunity, including pregnant women. Despite introducing the vaccine as the proper means to curb the ...*

Authors: Martine Kallimbu, Mughwira Mwangi, Phares Mujinja, Pankras Luoga and Thadeus Ruwaichi

Citation: BMC Public Health 2024 24:2481

Content type: Research Published on: 12 September 2024

**Development and validation of the mpox stigma scale (MSS) and mpox knowledge scale (MKS)**

*Few validated brief scales are available to measure constructs that may hinder mpox-related prevention and care engagement, such as knowledge and stigma. Both are highly salient barriers to infectious disease ...*

Authors: Henna Budhwani, Ibrahim Yigit, Jacob B. Stocks, Marie C.D. Stoner, Erica Browne, Audrey E. Pettifor and Lisa B. Hightow-Weidman

Citation: BMC Public Health 2024 24:2469

Content type: Research Published on: 10 September 2024

**BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 14 Sep 2024)

[No new digest content identified]

**BMJ Evidence-Based Medicine**

August 2024 - Volume 29 - 4

<https://ebm.bmj.com/content/29/4>

[Reviewed earlier]

**BMJ Global Health**

September 2024 - Volume 9 - 9

<https://gh.bmj.com/content/9/9>

*Original research*

**The global health and economic value of COVID-19 vaccination** (7 September, 2024)

JP Sevilla, Daria Burnes, Joseph S Knee, Manuela Di Fusco, Moe H Kyaw, Jingyan Yang, Jennifer L Nguyen, David E Bloom

We provide the first estimates of the broad value of CV incorporating GDP, QALY and direct and indirect cost impacts. Through December 2021, CV produced significant health and economic value, represented strong value for money and produced significant macroeconomic benefits that should be considered in vaccine evaluation.

## **Bulletin of the Atomic Scientists**

September 2024

<https://thebulletin.org/magazine/2024-09/>

[Reviewed earlier]

## **Bulletin of the World Health Organization**

Volume 102(9); 2024 Sep 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/469680/>

[Reviewed earlier]

## **Cell**

Sep 05, 2024 Volume 187 Issue 18 p4813-5118

<https://www.cell.com/cell/current>

*Commentary*

### **[The need to diversify genomic studies: Insights from Andean highlanders and Amazonians](#)**

Isabela Alvim, et al.

More globally diverse perspectives are needed in genomic studies and precision medicine practices on non-Europeans. Here, we illustrate this by discussing the distribution of clinically actionable genetic variants involved in drug response in Andean highlanders and Amazonians, considering their environment, history, genetic structure, and historical biases in the perception of biological diversity of Native Americans.

*Previews*

### **[Laws of thought in living cells](#)**

Carlise Sorenson, Katarzyna P. Adamala

Building biological computers is one of the most intensively pursued goals of modern synthetic biology. The new TriLoS tristate-based logic synthesis platform, published in this issue of Cell, offers a long-awaited solution to scale up the complexity of biocomputing, opening a path to move this field beyond proof-of-principle demonstrations.

### **[Multi-layered computational gene networks by engineered tristate logics](#)**

Jiawei Shao, et al.

*Open Access*

By using engineered tristate buffers as basic signal processing units in mammalian cells, various arithmetic logics of interest can be flexibly and systematically mapped to construct complex computational gene networks for diverse applications in biocomputation and cell-based therapies.

## **Child Care, Health and Development**

Volume 50, Issue 5 September 2024

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

## **Clinical Pharmacology & Therapeutics**

Volume 116, Issue 3 Pages: 479-874 September 2024

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

### ***Issue Focus: Getting the Dosage Right***

[Reviewed earlier]

**Clinical Therapeutics**

September 2024 Volume 46 Issue 9 p661-726

<http://www.clinicaltherapeutics.com/current>

[New issue; No digest content identified]

**Clinical Trials**

Volume 21 Issue 4, August 2024

<https://journals.sagepub.com/toc/ctja/21/4>

[Reviewed earlier]

**Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 14 Sep 2024]

[No new digest content identified]

**Contemporary Clinical Trials**

Volume 144 September 2024

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/144/suppl/C>

[Reviewed earlier]

**The CRISPR Journal**

Volume 7, Issue 4 / August 2024

<https://www.liebertpub.com/toc/crispr/7/4>

[Reviewed earlier]

**Current Genetic Medicine Reports**

Volume 11, Issue 3-4 December 2023

<https://link.springer.com/journal/40142/volumes-and-issues/11-3>

[Reviewed earlier]

**Current Medical Research and Opinion**

Volume 40, Issue 8 2024

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

**Current Opinion in Infectious Diseases**

August 2024 - Volume 37 - Issue 4

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

**Current Protocols in Human Genetics**

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 14 Sep 2024]  
[No new digest content identified]

### **Developing World Bioethics**

Volume 24, Issue 3 Pages: 135-261 September 2024  
<https://onlinelibrary.wiley.com/toc/14718847/current>  
[Reviewed earlier]

### **Development in Practice**

Volume 34, Issue 6, 2024  
<https://www.tandfonline.com/toc/cdip20/34/6>  
[New issue; No digest content identified]

### **Development Policy Review**

Volume 42, Issue 5 September 2024  
<https://onlinelibrary.wiley.com/toc/14677679/current>  
[Reviewed earlier]

### **Disaster Medicine and Public Health Preparedness**

Volume 18 - 2024  
<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>  
[Reviewed earlier]

### **Disasters**

Volume 48, Issue 3 July 2024  
<https://onlinelibrary.wiley.com/toc/14677717/2024/48/3>  
[Reviewed earlier]

### **EMBO Reports**

Volume 25 Issue 9 10 September 2024  
<https://www.embopress.org/toc/14693178/current>  
*Opinion* 14 August 2024

#### **[Genetic information and insurance](#)**

Frank Gannon

The use of genetic data for diagnosis increases the risk of genetic discrimination by insurance companies and could hinder progress in medicine.

### **Emerging Infectious Diseases**

Volume 30, Number 9—September 2024  
<http://wwwnc.cdc.gov/eid/>

*Synopses*

**[Onward Virus Transmission after Measles Secondary Vaccination Failure](#)** [PDF - 950 KB - 8 pages]

I. Tranter et al.

**Use of Open-Source Epidemic Intelligence for Infectious Disease Outbreaks, Ukraine, 2022**  
**[PDF - 693 KB - 7 pages]**

A. Kannan et al.

**Effects of Rotavirus Vaccination Coverage among Infants on Hospital Admission for Gastroenteritis across All Age Groups, Japan, 2011–2019** **[PDF - 879 KB - 8 pages]**

K. Kishimoto et al.

**Epidemics**

Volume 48 September 2024

<https://www.sciencedirect.com/journal/epidemics/vol/48/suppl/C>

*Review article Open access*

**Inference of epidemic dynamics in the COVID-19 era and beyond**

Anne Cori, Adam Kucharski

Article 100784

**Epidemiology and Infection**

Volume 152 - 2024

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

**Ethics & Human Research**

Volume 46, Issue 4 Pages: 1-51 July–August 2024

<https://onlinelibrary.wiley.com/toc/25782363/current>

***Research with refugee populations Ethical considerations for crowdsourced research***

[Reviewed earlier]

**Ethics & International Affairs**

Volume 37 - Issue 4 - Winter 2023

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

**Ethics, Medicine and Public Health**

Volume 31 (December 2023)

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C>

[Reviewed earlier]

**The European Journal of Public Health**

Volume 34, Issue 4, August 2024

<https://academic.oup.com/eurpub/issue/34/4>

[Reviewed earlier]

**Expert Review of Vaccines**

Vol 23 (1) 2023

<https://www.tandfonline.com/toc/ierv20/current>  
[Reviewed earlier]

### **Foreign Affairs**

July/August 2024 Volume 103, Number 4  
<https://www.foreignaffairs.com/issues/2023/103/4>  
[Reviewed earlier]

### **Forum for Development Studies**

Volume 51, 2024 - Issue 2  
<http://www.tandfonline.com/toc/sfds20/current>  
[Reviewed earlier]

### **Genetics in Medicines**

Volume 26, Issue 9 September 2024  
<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/26/issue/9>  
[Reviewed earlier]

### **Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>  
[Accessed 14 Sep 2024]  
[No new digest content identified]

### **Global Health Action**

Volume 17, Issue 1 (2024)  
<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>  
[Reviewed earlier]

### **Global Health: Science and Practice (GHSP)**

Vol. 12, No. 4 August 27, 2024  
<http://www.ghspjournal.org/content/current>  
[Reviewed earlier]

### **Global Legal Monitor & Legal Reports – Library of Congress/USA**

<https://www.loc.gov/collections/global-legal-monitor/>  
[https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date\\_desc](https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc)  
[Accessed 14 Sep 2024]  
*Article*

### **[European Union: General Court Rules European Commission Must Grant Wider Access to COVID-19 Vaccine Purchase Agreements](#)**

On July 17, 2024, the General Court of the European Union (EU) held that under an EU freedom of information law, the European Commission (Commission) failed to give sufficient public access to COVID-19 vaccine purchase agreements. Six members of the European Parliament (MEPs) had brought



an action for annulment before the court and requested access ... Continue reading "European Union: General Court Rules European...  
Contributor: Gesley, Jenny  
Date: 2024-09-04

### **Global Public Health**

Volume 19, Issue 1 (2024)  
<http://www.tandfonline.com/toc/rgph20/current>  
[Reviewed earlier]

### **Globalization and Health**

<http://www.globalizationandhealth.com/>  
[Accessed 14 Sep 2024]  
[No new digest content identified]

### **Health and Human Rights**

Volume 26, Issue 1, June 2024  
<https://www.hhrjournal.org/volume-26-issue-1-june-2024/>  
***SPECIAL SECTION – COMMEMORATING 30 YEARS***  
[Reviewed earlier]

### **Health Economics, Policy and Law**

Volume 19 - Issue 2 - April 2024  
<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>  
[Reviewed earlier]

### **Health Policy and Planning**

Volume 39, Issue 8, October 2024  
<https://academic.oup.com/heapol/issue/39/8>  
*Original Article*  
[\*\*Shifting patterns and competing explanations for infectious disease priority in global health agenda setting arenas\*\*](#)  
Stephanie L Smith and others

### **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>  
[Accessed 14 Sep 2024]  
[No new digest content identified]

### **Human Gene Therapy**

Volume 35, Issue 15-16 / August 2024  
<https://www.liebertpub.com/toc/hum/35/15-16>  
[Reviewed earlier]

## Humanitarian Practice Network

<https://odihpn.org/>

*Featured Publications*

[No new digest content identified]

## Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 20 Issue 1, 2024

<https://www.tandfonline.com/toc/khvi20/20/1?nav=tocList>

*Selected Content*

[Reviewed earlier]

## Immunity

Aug 13, 2024 Volume 57 Issue 8 p1713-1994

<https://www.cell.com/immunity/current>

[Reviewed earlier]

## Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 14 Sep 2024]

[No new digest content identified]

## Infectious Diseases of Poverty

<http://www.idpjournals.com/content>

[Accessed 14 Sep 2024]

**[Global patterns of syphilis, gonococcal infection, typhoid fever, paratyphoid fever, diphtheria, pertussis, tetanus, and leprosy from 1990 to 2021: findings from the Global Burden of Disease Study 2021](#)**

Authors: Weiye Chen, Yiming Chen, Zile Cheng, Yiwen Chen, Chao Lv, Lingchao Ma, Nan Zhou, Jing Qian, Chang Liu, Min Li, Xiaokui Guo and Yongzhang Zhu

Content type: Research Article 13 September 2024

### *Results*

By 2021, among the eight diseases, gonococcal infection had the highest global ASIR [1096.58 per 100,000 population, 95% uncertainty interval (UI): 838.70, 1385.47 per 100,000 population], and syphilis had the highest global age-standardized DALY rate (107.13 per 100,000 population, 95% UI: 41.77, 212.12 per 100,000 population). Except for syphilis and gonococcal infection, the age-standardized DALY rate of the remaining diseases decreased by at least 55% compared to 1990, with tetanus showing the largest decrease by at least 90%. Globally, significant declines in the ASIR, age-standardized DALY rate, and ASMR for these eight bacterial infections have been observed in association with increases in the SDI. Regions with lower SDI, such as sub-Saharan Africa, experienced a relatively higher burden of these eight bacterial infections.

### *Conclusions*

Although there has been an overall decline in these eight diseases, they continue to pose significant public health challenges, particularly in low SDI regions. To further reduce this burden in these areas, targeted intervention strategies are essential, including multi-sectoral collaboration, policy support, improved WASH management, and enhanced research efforts.

## International Health

Volume 16, Issue 5, September 2024  
<https://academic.oup.com/inthealth/issue/16/5>  
[Reviewed earlier]

### **International Human Rights Law Review**

Volume 13 (2024): Issue 1 (Jun 2024):  
<https://brill.com/view/journals/hrlr/13/1/hrlr.13.issue-1.xml>  
***Special Issue on Inter-State Communications***  
Table of Contents  
[Reviewed earlier]

### **International Journal of Community Medicine and Public Health**

Vol. 11 No. 9 (2024): September 2024  
<https://www.ijcmph.com/index.php/ijcmph/issue/view/116>  
*Original Research Articles*  
**[Immunization coverage and factors associated with immunization status in an urban area of Imphal East district: a cross-sectional study](#)**  
Usha D. Thounaojam, Bishwalata Rajkumari, Laishram R. Chanu, Milachon Kasar, Oinam G. Devi, Rajkumar Ranalcis, Thaimei Gairanlung  
3444-3451  
DOI: [10.18203/2394-6040.ijcmph20242293](https://doi.org/10.18203/2394-6040.ijcmph20242293)  
**[Time series analysis of chickenpox cases admitted in infectious disease hospital in a metropolitan city, Mumbai, India](#)**  
Prahatheeswaran G., Pavan Laxman Sable, Sowntappan Balasubramanian  
3466-3471  
DOI: [10.18203/2394-6040.ijcmph20242543](https://doi.org/10.18203/2394-6040.ijcmph20242543)

### **International Journal of Epidemiology**

Volume 53, Issue 4, August 2024  
<https://academic.oup.com/ije/issue/53/4>  
[New issue; No digest content identified]

### **International Journal of Human Rights in Healthcare**

Volume 17 Issue 3 2024  
<https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/3>  
*Table of contents*  
[Reviewed earlier]

### **JAMA**

September 10, 2024, Vol 332, No. 10, Pages 773-850  
<https://jamanetwork.com/journals/jama/currentissue>  
*Viewpoint*  
*AI in Medicine*  
**[A Federated Registration System for Artificial Intelligence in Health](#)**  
Michael J. Pencina, PhD; Jonathan McCall, MS; Nicoleta J. Economou-Zavlanos, PhD  
JAMA. 2024;332(10):789-790. doi:10.1001/jama.2024.14026

This Viewpoint discusses a suggested framework of local registries to record and track all health artificial intelligence technologies used in clinical care, with the goal of providing transparency on these technologies and helping speed adoption while also protecting patient well-being.

### **JAMA Health Forum**

September 2024, Vol 5, No. 9

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

### **JAMA Pediatrics**

September 2024, Vol 178, No. 9, Pages 847-956

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

### **JB I Evidence Synthesis**

August 2024 - Volume 22 - Issue 8

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

### **Journal of Adolescent Health**

September 2024 Volume 75 Issue 3 p375-52

<https://www.jahonline.org/current>

[Reviewed earlier]

### **Journal of Artificial Intelligence Research**

Vol. 80 (2024)

<https://www.jair.org/index.php/jair>

*Contents*

[Reviewed earlier]

### **Journal of Community Health**

Volume 49, Issue 4 August 2024

<https://link.springer.com/journal/10900/volumes-and-issues/49-4>

[Reviewed earlier]

### **Journal of Current Medical Research and Opinion**

*...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.*

Vol. 7 No. 01 (2024), January 2, 2024 , Page 1988-1996

<https://www.cmro.in/index.php/jcmro/issue/view/75>

[Reviewed earlier]

### **Journal of Development Economics**

Volume 170 September 2024

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/170/suppl/C>

[Reviewed earlier]

### **Journal of Empirical Research on Human Research Ethics**

Volume 19 Issue 3, July 2024

<http://journals.sagepub.com/toc/jre/current>

***Special Issues in Research and IRB/REC Functioning, Including the use of AI***

[Reviewed earlier]

### **Journal of Epidemiology & Community Health**

August 2024 - Volume 78 - 8

<https://jech.bmj.com/content/78/8>

[Reviewed earlier]

### **Journal of Evidence-Based Medicine**

Volume 17, Issue 2 Pages: 237-467 June 2024

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

### **Journal of Global Ethics**

Volume 20, Issue 1 (2024)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

### **Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 35, Number 3, August 2024

<https://muse.jhu.edu/issue/52935>

*Table of Contents*

[Reviewed earlier]

### **Journal of Immigrant and Minority Health**

Volume 26, Issue 4 August 2024

<https://link.springer.com/journal/10903/volumes-and-issues/26-4>

[Reviewed earlier]

### **Journal of Immigrant & Refugee Studies**

Volume 22, 2024 \_ Issue 3

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

### **Journal of International Development**

Volume 36, Issue 6 Pages: 3-2669 August 2024

<https://onlinelibrary.wiley.com/toc/10991328/current>

[New issue; No digest content identified]

**Journal of Medical Ethics**

September 2024 - Volume 50 - 9

<http://jme.bmj.com/content/current>

[Reviewed earlier]

**Journal of Patient-Centered Research and Reviews**

Volume 11, Issue 1 (2024)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

**The Journal of Pediatrics**

Volume 272 September 2024

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/272/suppl/C>

[New issue; No digest content identified]

**Journal of Pharmaceutical Policy and Practice**

Volume 17, Issue 1 (2024) Issue 1

<https://www.tandfonline.com/toc/jppp20/17/1>

[Reviewed earlier]

**Journal of Public Health Management & Practice**

July/August 2024 - Volume 30 - Issue 4

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

**Journal of Public Health Policy**

Volume 45, issue 3, September 2024

<https://link.springer.com/journal/41271/volumes-and-issues/45-3>

[Reviewed earlier]

**Journal of the Royal Society – Interface**

September 2024 Volume 21 Issue 218

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

**Journal of Travel Medicine**

Volume 31, Issue 6, August 2024

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

**Journal of Virology**

Volume 98 • Number 6 • June 2024  
<http://jvi.asm.org/content/current>  
[Reviewed earlier]

### **The Lancet**

Sep 14, 2024 Volume 404 Number 10457 p991-1076  
<https://www.thelancet.com/journals/lancet/issue/current>  
[New issue; No digest content identified]

### **The Lancet Child & Adolescent Health**

Sep 2024 Volume 8 Number 9 p611-706, e7-e11  
<https://www.thelancet.com/journals/lanchi/issue/current>  
[New issue; No digest content identified]

### **Lancet Digital Health**

Sep 2024 Volume 6 Number 9 e601-e672  
<https://www.thelancet.com/journals/landig/issue/current>  
*Editorial*

#### **[Balancing AI innovation with patient safety](#)**

The Lancet Digital Health

#### *Viewpoint*

#### **[A future role for health applications of large language models depends on regulators enforcing safety standards](#)**

Oscar Freyer, Isabella Catharina Wiest, Jakob Nikolas Kather, Stephen Gilbert

### **Lancet Global Health**

Sep 2024 Volume 12 Number 9 e1370-e1559  
<https://www.thelancet.com/journals/langlo/issue/current>  
*Comment*

#### **[Rotavirus immunisation benefits and implications in low-income countries](#)**

Nazish Bostan, Sadia Sattar, Sundus Javed

#### *Articles*

#### **[Population size, HIV prevalence, and antiretroviral therapy coverage among key populations in sub-Saharan Africa: collation and synthesis of survey data, 2010–23](#)**

Oliver Stevens, et al.

#### **[Prevalence of syphilis among adults and adolescents in five sub-Saharan African countries: findings from Population-based HIV Impact Assessment surveys](#)**

Mansoor Farahani, et al.

#### **[Long-term effect of pneumococcal conjugate vaccines on invasive pneumococcal disease incidence among people of all ages from national, active, laboratory-based surveillance in South Africa, 2005–19: a cohort observational study](#)**

Anne von Gottberg, et al. on behalf of GERMS-SA

**Re-evaluating the impact and cost-effectiveness of pneumococcal conjugate vaccine introduction in 112 low-income and middle-income countries in children younger than 5 years: a modelling study**

Cynthia Chen, et al.

**Effectiveness and impact of monovalent rotavirus vaccination in Afghanistan: a test-negative case-control analysis**

Palwasha Anwari, et al.

*Health Policy*

**WHO global research priorities for sexually transmitted infections**

Sami L Gottlieb, et al.

**Lancet Infectious Diseases**

Sep 2024 Volume 24 Number 9 p935-1058, e540-e601

<https://www.thelancet.com/journals/laninf/issue/current>

*Editorial*

**Oropouche fever, the mysterious threat**

The Lancet Infectious Diseases

*Review*

**The epidemiology, transmission, diagnosis, and management of drug-resistant tuberculosis—lessons from the South African experience**

Kogieleum Naidoo, et al.

**Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UK**

Shamez N Ladhani, et al.

*Personal View*

**Accelerating antibiotic access and stewardship: a new model to safeguard public health**

Jennifer Cohn, et al.

**Lancet Public Health**

Sep 2024 Volume 9 Number 9 e635-e708

<https://www.thelancet.com/journals/lanpub/issue/current>

*Comment*

**New-generation pneumococcal vaccines for children**

Philippe De Wals

*Articles*

**Potential impact of replacing the 13-valent pneumococcal conjugate vaccine with 15-valent or 20-valent pneumococcal conjugate vaccine in the 1 + 1 infant schedule in England: a modelling study**

Yoon Hong Choi, et al.

**The role of mental illness and neurodevelopmental conditions in human papillomavirus vaccination uptake within the Swedish school-based vaccination programme: a population-based cohort study**

Kejia Hu, et al.



Despite documented mental illness-related disparities in cervical cancer screening and incidence, insufficient data exist on differences in cervical cancer prevention strategies, such as human papillomavirus (HPV) vaccination. We aimed to investigate the association of mental illness and neurodevelopmental conditions among girls and their parents with uptake of HPV vaccination in Sweden.

#### *Viewpoint*

#### **Financialisation: a 21st century commercial determinant of health equity**

Sharon Friel, et al.

#### *Summary*

In 21st century capitalism, financial markets reign supreme. The elevation of investing, trading, and speculating as a way of making profit has shifted economic power towards institutional investors and enhanced the power of financial capital. Financialisation has introduced uncertainty in the commitment to public provision of goods and services. The behaviours of corporations focus more on profit for shareholders and senior executives to the detriment of wages, worker protections, livelihoods, and impact on prices and the environment. The practices of this financial system pose major challenges to public health and planetary health equity through the influence on social inequality, climate change, and health outcomes. The aim of this Viewpoint is to expand the understanding of the commercial determinants of health to explicitly include the financial system and present key plausible pathways via which the financialisation of advanced economies influences public health and planetary health equity. The global public health community must pay close attention to these key commercial determinants of health. It is now crucial to reduce the power of financial actors and hold financial actors accountable. Civil society groups can highlight their practices, articulate alternative visions, and hold financial actors and governments to account. Interdisciplinary research must provide a diagnosis of the financial and public health issues, and, importantly, illuminate effective pathways forward. Financial and commercial worlds must return to stakeholder primacy rather than that of the shareholder.

#### **Lancet Respiratory Medicine**

Sep 2024 Volume 12 Number 9 p655-742, e52-e56

<https://www.thelancet.com/journals/lanres/issue/current>

#### *Editorial*

#### **FLiRTing with danger as SARS-CoV-2 variants evolve**

The Lancet Respiratory Medicine

#### *Articles*

#### **Estimated number of lives directly saved by COVID-19 vaccination programmes in the WHO European Region from December, 2020, to March, 2023: a retrospective surveillance study**

Margaux M I Meslé, et al. on behalf of The WHO European Respiratory Surveillance Network

#### *Summary*

#### *Background*

By March, 2023, 54 countries, areas, and territories (hereafter CAT) in the WHO European Region had reported more than 2·2 million COVID-19-related deaths to the WHO Regional Office for Europe. Here, we estimated how many lives were directly saved by vaccinating adults in the WHO European Region from December, 2020, to March, 2023.

#### *Methods*

In this retrospective surveillance study, we estimated the number of lives directly saved by age group, vaccine dose, and circulating variant-of-concern (VOC) period, regionally and nationally, using weekly data on COVID-19 mortality and infection, COVID-19 vaccination uptake, and SARS-CoV-2 virus characterisations by lineage downloaded from The European Surveillance System on June 11, 2023, as well as vaccine effectiveness data from the literature. We included data for six age groups (25–49

years, 50–59 years, ≥60 years, 60–69 years, 70–79 years, and ≥80 years). To be included in the analysis, CAT needed to have reported both COVID-19 vaccination and mortality data for at least one of the four older age groups. Only CAT that reported weekly data for both COVID-19 vaccination and mortality by age group for 90% of study weeks or more in the full study period were included. We calculated the percentage reduction in the number of expected and reported deaths.

#### Findings

Between December, 2020, and March, 2023, in 34 of 54 CAT included in the analysis, COVID-19 vaccines reduced deaths by 59% overall (CAT range 17–82%), representing approximately 1·6 million lives saved (range 1·5–1·7 million) in those aged 25 years or older: 96% of lives saved were aged 60 years or older and 52% were aged 80 years or older; first boosters saved 51% of lives, and 60% were saved during the Omicron period.

#### Interpretation

Over nearly 2·5 years, most lives saved by COVID-19 vaccination were in older adults by first booster dose and during the Omicron period, reinforcing the importance of up-to-date vaccination among the most at-risk individuals. Further modelling work should evaluate indirect effects of vaccination and public health and social measures.

### **Maternal and Child Health Journal**

Volume 28, Issue 7 July 2024

<https://link.springer.com/journal/10995/volumes-and-issues/28-7>

[Reviewed earlier]

### **Medical Decision Making (MDM)**

Volume 44 Issue 6, August 2024

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

### **The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 102, Issue 2 Pages: 271-516 June 2024

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

### **Molecular Therapy**

Sep 04, 2024 Volume 32 Issue 9 p2801-3194

<https://www.cell.com/molecular-therapy/current>

*Editorials*

#### **Staying on target in gene and cell therapy**

Rory Bricker-Anthony, Dwight D. Koeberl, Gerald S. Lipshutz, Fabiana Perna

We live in a new world of therapies targeting cancer and genetic disease, as highlighted by recent breakthroughs in cell and gene therapy. These therapies can be termed genetic, whether they use viral or nonviral vectors or mRNA.<sup>1</sup> However, a key hurdle for all such therapies is the need for endpoints in clinical trials that detect bioactivity and efficacy, which can potentially be obtained by using biomarkers related to molecular markers for disease involvement. This special issue of Molecular Therapy, "Targets and Biomarkers," focuses on the development of such biomarkers, as well as the clinical development of new therapies for unmet needs, with a special emphasis on the field of cancer therapeutics.

#### **Rapidly evolving genome and epigenome editing technologies**

Ngoc Tung Tran, Renzhi Han

Genome editing technologies are rapidly evolving, from the early zinc-finger nucleases, transcription activator-like effector nucleases (TALENs), and CRISPR-Cas9 (Figure 1, initial genome editing technologies), which generate double-strand breaks (DSBs), to base editing, which makes precise nucleobase conversion without inducing DSBs, and prime editing, which can carry out all types of edits without DSBs or donor DNA templates. The emergence of these revolutionary technologies offers us unprecedented opportunities for biomedical research and therapy development.

## **Nature**

Volume 633 Issue 8029, 12 September 2024

<https://www.nature.com/nature/volumes/633/issues/8029>

*Editorial* 10 Sep 2024

### **[Mpox: apply COVID lessons to control outbreak in Africa](#)**

As mpox becomes a global health emergency, global health leaders must better coordinate their plans and pharmaceutical companies must be prepared to make vaccines affordable.

## **Nature Biotechnology**

Volume 42 Issue 8, August 2024

<https://www.nature.com/nbt/volumes/42/issues/8>

[Reviewed earlier]

## **Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 14 Sep 2024)

[No new digest content identified]

## **Nature Genetics**

Volume 56 Issue 8, August 2024

<https://www.nature.com/ng/volumes/56/issues/8>

[Reviewed earlier]

## **Nature Human Behaviour**

Volume 8 Issue 8, August 2024

<https://www.nature.com/nathumbehav/volumes/8/issues/8>

*Research Briefing* 25 Jul 2024

### **[New and re-emerging disease outbreaks can cause social conflict](#)**

Analysis of a dataset on zoonotic diseases such as Ebola and avian flu reveals that although zoonotic outbreaks can reduce the incidence of civil war, they increase social conflicts that involve civil defence groups, vigilantes and other identity militias.

## **Nature Medicine**

Volume 30 Issue 8, August 2024

<https://www.nature.com/nm/volumes/30/issues/8>

[Reviewed earlier]

## **Nature Reviews Drug Discovery**

Volume 23 Issue 9, September 2024

<https://www.nature.com/nrd/volumes/23/issues/9>

*Comment* 15 Jul 2024

### **[Data science in pharmaceutical R&D: the DISRUPT-DS industry roundtable](#)**

The DISRUPT-DS roundtable, which brings together data science leaders from large pharmaceutical companies, aims to be a forum for sharing experiences and networking, for shaping industry-level topics and for amplifying the role of data science across pharmaceutical R&D.

Najat S. Khan, Thomas Senderovitz, Christoph Meier

*Biobusiness Briefs* 06 Aug 2024

### **[Comprehensive measurement of biopharmaceutical R&D investment](#)**

Amitabh Chandra, John Drum, Noam Kirson

## **Nature Reviews Genetics**

Volume 25 Issue 9, September 2024

<https://www.nature.com/nrg/volumes/25/issues/9>

*Review Article* 24 Apr 2024

### **[Targeted genome-modification tools and their advanced applications in crop breeding](#)**

Targeted genome modification using CRISPR–Cas genome editing, base editing or prime editing is driving base research in plants and precise molecular breeding. The authors review the technological principles underlying these methods, approaches for their delivery in plants, and emerging crop-breeding strategies based on targeted genome modification.

Boshu Li, Chao Sun, Caixia Gao

## **Nature Reviews Immunology**

Volume 24 Issue 9, September 2024

<https://www.nature.com/nri/volumes/24/issues/9>

[New issue; No digest content identified]

## **New England Journal of Medicine**

Volume 391 No. 10 September 12, 2024

<https://www.nejm.org/toc/nejm/medical-journal>

[New issue; No digest content identified]

## **NEJM Evidence**

Volume 3 No. 9 September 2024

<https://evidence.nejm.org/toc/evid/current>

*NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.*

*Clinical Trials Workshop*

### **[The Case for Access to Data Monitoring Committee Charters](#)**

D. Zarin and Others

*Abstract*

Clinical trials investigating novel or high-risk interventions often use data monitoring committees (DMCs) to ensure that the participants' best interests are safeguarded. The typical DMC charter describes procedures by which the DMC operates, including important details concerning organizational structure, membership, meeting frequency, statistical monitoring guidelines, and contents of DMC

reports for interim review. These charters, however, are not routinely publicly available; in some cases, their access could be important to the interpretation of trial results. We recommend including DMC charters for such trials in ClinicalTrials.gov at the time of trial completion; trial protocols, informed consent documents, and statistical analysis plans are already available in this repository.

## **njp Vaccines**

<https://www.nature.com/npjvaccines/>

[Accessed 14 Sep 2024]

*Article*

### **COVID-19 vaccine refusal is driven by deliberate ignorance and cognitive distortions**

Kamil Fuławka, Ralph Hertwig, Thorsten Pachur

14 Sep 2024

*Article Open access*

### **Understanding the rationales and information environments for early, late, and nonadopters of the COVID-19 vaccine**

Published: 14 September 2024

## **Pediatrics**

Volume 154, Issue 3 September 2024

<https://publications.aap.org/pediatrics/issue/154/3>

[New issue; No digest content identified]

## **PharmacoEconomics**

Volume 42, Issue 9 September 2024

<https://link.springer.com/journal/40273/volumes-and-issues/42-9>

[Reviewed earlier]

## **PLoS Biology**

<https://journals.plos.org/plosbiology/>

(Accessed 14 Sep 2024)

[No new digest content identified]

## **PLoS Genetics**

<https://journals.plos.org/plosgenetics/>

(Accessed 14 Sep 2024)

[No new digest content identified]

## **PLoS Global Public Health**

[https://journals.plos.org/globalpublichealth/search?sortOrder=DATE\\_NEWEST\\_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60](https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60)

(Accessed 14 Sep 2024)

### **Financing for equity for women's, children's and adolescents' health in low- and middle-income countries: A scoping review**

Lama Bou-Karroum, Domenico G. Iaia, Fadi El-Jardali, Clara Abou Samra, Sabine Salameh, Zeina Sleem, Reem Masri, Aya Harb, Nour Hemadi, Nadeen Hilal, Layal Hneiny, Sahar Nassour, Mehr Gul Shah, Etienne V. Langlois

Research Article | published 12 Sep 2024 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0003573>

### **PLoS Medicine**

<https://journals.plos.org/plosmedicine/>

(Accessed 14 Sep 2024)

[No new digest content identified]

### **PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

(Accessed 14 Sep 2024)

[No new digest content identified]

### **PLoS One**

<http://www.plosone.org/>

[Accessed 14 Sep 2024]

#### **[Immunogenicity and real-world effectiveness of COVID-19 vaccines in Lebanon: Insights from primary and booster schemes, variants, infections, and hospitalization](#)**

Rima Moghnieh, Wajdi Haddad, Nayla Jbeily, Salam El-Hassan, Shadi Eid, Hicham Baba, Marilyne Sily, Yara Saber, Dania Abdallah, Abdul Rahman Bizri, Mohamed H. Sayegh

Research Article | published 13 Sep 2024 PLOS ONE

<https://doi.org/10.1371/journal.pone.0306457>

#### **[Economic evaluation on meningococcal vaccination strategies among children under nine years of age in Zhejiang province, China](#)**

Jianying Shen, Chai Ji, Xiaofu Luo, Yu Hu

Research Article | published 09 Sep 2024 PLOS ONE

<https://doi.org/10.1371/journal.pone.0310274>

### **PLoS Pathogens**

<http://journals.plos.org/plospathogens/>

[Accessed 14 Sep 2024]

[No new digest content identified]

### **PNAS - Proceedings of the National Academy of Sciences of the United States**

September 10, 2024 vol. 121 no. 37

<https://www.pnas.org/toc/pnas/121/37>

[New issue; No digest content identified]

### **PNAS Nexus**

Volume 3, Issue 8, August 2024

<https://academic.oup.com/pnasnexus/issue/3/8>

[New issue; No digest content identified]

### **Prehospital & Disaster Medicine**

Volume 39 - Issue 2 - April 2024

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

### **Preventive Medicine**

Volume 184 July 2024

<https://www.sciencedirect.com/journal/preventive-medicine/vol/184/suppl/C>

[Reviewed earlier]

### **Proceedings of the Royal Society B**

September 2024 Volume 291 Issue 2030

<https://royalsocietypublishing.org/toc/rspb/current>

[New issue; No digest content identified]

### **Public Health**

Volume 235 Pages 1-218 (October 2024)

<https://www.sciencedirect.com/journal/public-health/vol/235/suppl/C>

*Review article Abstract only*

**[Comparing higher-dose and single standard-dose influenza vaccines in preventing cardiovascular events: a meta-analysis with 68,713 patients](#)**

F. Omid, M. Rahmanna, F. Khalili, A.H. Shahidi Bonjar, M.J. Nasiri

Pages 71-75

*Research article Abstract only*

**[Global burden of childhood nutritional deficiencies, 1990–2019](#)**

Zihao Liu, Ying Duan, Ling Yang, Jing Du, Huaqing Liu

Pages 26-32

*Research article Open access*

**[Global associations between the use of basic drinking water and sanitation services with diarrhoeal disease incidence in 200 countries and territories from 2000 to 2019](#)**

Qiao Liu, Min Liu, Jue Liu

Pages 202-210

### **Public Health Ethics**

Volume 17, Issue 1-2, April/July 2024

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

### **Public Health Genomics**

2024, Vol. 27, No. 1

<https://karger.com/phg/issue/27/1>

[Reviewed earlier]

## **Public Health Reports**

Volume 139 Issue 4, July/August 2024

<https://journals.sagepub.com/toc/phrg/139/4>

[Reviewed earlier]

## **Qualitative Health Research**

Volume 34 Issue 10, August 2024

<https://journals.sagepub.com/toc/QHR/current>

[New issue; No digest content identified]

## **Research Ethics**

Volume 20 Issue 3, July 2024

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

## **Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 14 Sep 2024]

[No new digest content identified]

## **Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

*Latest Articles*

[Together towards tomorrow: partnerships powering the digital transformation of the health sector](#)

Silva Jr. et al.

## **Risk Analysis**

Volume 44, Issue 9 Pages: 1977-2311 September 2024

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

## **Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 14 Sep 2024]

[Reviewed earlier]

## **Science**

Volume 385| Issue 6714| 13 Sep 2024

<https://www.science.org/toc/science/current>

*Perspectives*

[Generative AI as a tool for truth](#)

BY Bence Bago, Jean-François Bonnefon



12 Sep 2024: 1164-1165

Conversation with a trained chatbot can reduce conspiratorial beliefs

*Policy Forum*

**[Open access is shaping scientific communication](#)**

BY Mark J. McCabe, Frank Mueller-Langer

12 Sep 2024: 1170-1172

Funders and publishers should roll out policies in ways to support their evaluation

**Science and Engineering Ethics**

Volume 30, Issue 5 October 2024

<https://link.springer.com/journal/11948/volumes-and-issues/30-5>

**[Cross-National Variations in Scientific Ethics: Exploring Ethical Perspectives Among Scientists in China, the US, and the UK](#)**

Di Di, Elaine Howard Ecklund

Original Research/Scholarship Open access 11 September 2024 Article: 41

**Science Translational Medicine**

Volume 16| Issue 764| 11 Sep 2024

<https://www.science.org/toc/stm/current>

*Research Articles*

**[A spatially resolved single-cell lung atlas integrated with clinical and blood signatures distinguishes COVID-19 disease trajectories](#)**

BY João Da Silva Filho, et al.

11 Sep 2024

COVID-19 is characterized by a broad range of symptoms and disease trajectories. Understanding the correlation between clinical biomarkers and lung pathology during acute COVID-19 is necessary to understand its diverse pathogenesis and inform more ...

**Scientific Reports**

<https://www.nature.com/srep/articles?type=article>

[Accessed 14 Sep 2024]

[No new digest content identified]

**Social Science & Medicine**

Volume 350 June 2024

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/350/suppl/C>

[Reviewed earlier]

**Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 14 Sep 2024]

[No new digest content identified]

**Theoretical Medicine and Bioethics**

Volume 45, Issue 5 October 2024

<https://link.springer.com/journal/11017/volumes-and-issues/45-5>

[Reviewed earlier]

## **Travel Medicine and Infectious Diseases**

Volume 61 September–October 2024

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/61/suppl/C>

Editorial Open access

### **[Mpox strikes once more in 2024: Declared again as a public health emergency of international concern](#)**

Ranjit Sah, Vasso Apostolopoulos, Rachana Mehta, Ranjana Rohilla, ... Alfonso J. Rodriguez-Morales  
Article 102753

*Review article Open access*

### **[Global perspective of the risks of falsified and counterfeit medicines: A critical review of the literature](#)**

Aonghus J. Feeney, Jeffery A. Goad, Gerard T. Flaherty  
Article 102758

## **Tropical Medicine & International Health**

Volume 29, Issue 9 Pages: i-iv, 757-847 September 2024

<https://onlinelibrary.wiley.com/toc/13653156/current>

RESEARCH ARTICLE Open Access

### **[Epidemiology of infectious diseases in migrant populations from endemic or high-endemic countries: A multicentric primary care-based study in Spain](#)**

Angeline Cruz, Ethel Sequeira-Aymar, Alessandra Queiroga Gonçalves, Laura Camps-Vila, Marta M. Monclús-González, Elisa M. Revuelta-Muñoz, Núria Busquet-Solé, Susana Sarriegui-Domínguez, Aina Casellas, Alba Cuxart-Graell, M. Rosa Dalmau Llorca, Carina Aguilar-Martín, Ana Requena-Méndez  
Pages: 820-832

First Published: 19 July 2024

## **Vaccine**

Volume 42, Issue 23 3 October 2024

<https://www.sciencedirect.com/journal/vaccine/vol/42/issue/23>

Editorial

### **[Editorial: ML-driven vaccine against COVID-19: Developmental challenges and foresight](#)**

Dilbag Singh, Robertas Damaševičius, Vijay Kumar, Fabio Bagnoli, ... Rino Rappuoli  
Article 126267

*Conference info Abstract only*

### **[Proceedings of the dengue endgame summit: Imagining a world with dengue control](#)**

Adam D. Wegman, Shirin Kalimuddin, Ernesto T.A. Marques, Laura E. Adams, ... Adam T. Waickman  
Article 126071

*Review article Open access*

### **[Evaluation of the decision-making process underlying the initial off-label use of vaccines: A scoping review](#)**

Kelsey Adams, Dieynaba Diallo, Fazia Tadount, Verinsa Mouajou, Caroline Quach  
Article 126246

*Research article Abstract only*

**Measles immunity status in Iranian infants and children and outbreak concerns: Time for reconsidering the vaccination schedule?**

Babak Pourakbari, Shaghayegh Ashraf Talesh, Shima Mahmoudi, Maryam Sotoudeh, ... Setareh Mamishi

Article 126243

*Research article Abstract only*

**Determinants of undervaccination of routine childhood immunization in Argentina: A cross-sectional study**

Hannah Melchinger, Maike Winters, Sarah Christie, Nahuel Arias, ... Saad B. Omer

Article 126235

*Research article Open access*

**Human PapillomaVirus vaccination in gay and bi men: Predictors, dynamic norms, and connectedness to the LGBT+ community**

David Comer, Nikolett Zs. Warner, Chris Noone

Article 126014

*Research article Abstract only*

**Human papillomavirus vaccine beliefs and intentions Post-COVID-19 vaccine release among mothers in Alabama**

Kiley Brady, Alyssa Lee, John Bassler, Jennifer Young Pierce, Casey L. Daniel

Article 126046

*Research article Abstract only*

**Strategic vaccine stockpiles for regional epidemics of emerging viruses: A geospatial modeling framework**

Colin J. Carlson, Romain Garnier, Andrew Tiu, Stephen P. Luby, Shweta Bansal

Article 126051

*Research article Open access*

**Estimation of the poliovirus type 2 immunity gap in South Africa**

Lauren Brown, Jeremy Bingham, Juliet Pulliam, Zinhle Mthombothi, ... Cari van Schalkwyk

Article 126062

**Vaccines**

<https://www.mdpi.com/journal/vaccines>

[Accessed 14 Sep 2024]

[No new digest content identified]

**Value in Health**

September 2024 Volume 27 Issue 9 p1175-1310

<https://www.valueinhealthjournal.com/current>

SYSTEMATIC LITERATURE REVIEW

**Documenting the Full Value of Vaccination: A Systematic Review of Value Frameworks**

Abigail G. Riley, et al.

Published online: May 08, 2024 p1289-1299

Highlights

:: Stakeholders recognize the importance of understanding the full value of vaccination, including benefits and costs to patients, families, and broader society. However, broader value elements are rarely captured in economic evaluations of vaccination. Value frameworks can help decision makers evaluate the full value of vaccination by providing guidance on how to measure and incorporate broader value elements into economic evaluations.

:: In contrast to previous efforts, we searched for both vaccination-specific value frameworks and frameworks for other health interventions potentially relevant to the full value of vaccination. We found that broader value elements were not consistently included across all value frameworks, and vaccination frameworks excluded important value elements such as affordability and research and development costs. In addition, most value frameworks did not include clear guidance on measuring broader value elements.

:: Our findings identified key methodology gaps for incorporating broader value elements into vaccination value assessments. Future research should focus on developing clear guidelines on how to measure these elements to support empirical assessments of their impact on policy and decision making

## **World Development**

Volume 180 August 2024

<https://www.sciencedirect.com/journal/world-development/vol/180/suppl/C>

[New issue; No digest content identified]

.....  
.....

### ***Contents [click to move among sections]***

:: [\*Milestones, Perspectives\*](#)

:: [\*WHO\*](#)

:: [\*Organization Announcements\*](#)

:: [\*Journal Watch\*](#)

:: [\*Pre-Print Servers\*](#)

.....  
.....

## ***Pre-Print Servers***

### **arxiv**

<https://arxiv.org/>

[Accessed 14 Sep 2024]

[Filter: *Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics*]

### **[Analysis of Potential Biases and Validity of Studies Using Multiverse Approaches to Assess the Impacts of Government Responses to Epidemics](#)**

Jeremy D. Goldhaber-Fiebert

[Submitted on 11 Sep 2024]

We analyze the methodological approach and validity of interpretation of using national-level time-series regression analyses relating epidemic outcomes to policies that estimate many models involving permutations of analytic choices (i.e., a "multiverse" approach). Specifically, we evaluate the possible biases and pitfalls of interpretation of a multiverse approach to the context of government responses to epidemics using the example of COVID-19 and a recently published peer-reviewed paper by Bendavid and Patel (2024) along with the subsequent commentary that the two authors published discussing and interpreting the implications of their work. While we identify multiple potential errors and sources of

biases in how the specific analyses were undertaken that are also relevant for other studies employing similar approaches, our most important finding involves constructing a counterexample showing that causal model specification-agnostic multiverse analyses can be incorrectly used to suggest that no consistent effect can be discovered in data especially in cases where most specifications estimated with the data are far from causally valid. Finally, we suggest an alternative approach involving hypothesis-drive specifications that explicitly account for infectiousness across jurisdictions in the analysis as well as the interconnected ways that policies and behavioral responses may evolve within and across these jurisdictions.

## **Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 14 Sep 2024]

*Open Letter* metrics AWAITING PEER REVIEW

### **[Estimating the impact of vaccination: lessons learned in the first phase of the Vaccine Impact Modelling Consortium](#)**

[version 1; peer review: awaiting peer review]

Katy A M Gaythorpe, Xiang Li, Hannah Clapham, Emily Dansereau, Rich Fitzjohn, Wes Hinsley, Daniel Hogan, Mark Jit, Tewodaj Mengistu, T Alex Perkins, Allison Portnoy, Emilia Vynnycky, Kim Woodruff, Neil M Ferguson, Caroline L Trotter

Peer Reviewers Invited

- Funders
- Wellcome trust
- Medical Research Council

PUBLISHED 13 Sep 2024

## **medRxiv**

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 14 Sep 2024]

[Filter: All articles]

### **[A Framework to Assess Clinical Safety and Hallucination Rates of LLMs for Medical Text Summarisation](#)**

Elham Asgari, Nina Montana-Brown, Magda Dubois, Saleh Khalil, Jasmine Balloch, Dominic Pimenta  
medRxiv 2024.09.12.24313556; doi: <https://doi.org/10.1101/2024.09.12.24313556>

### **[Monkeypox in Europe: Epidemiology, Risk Factors and Implications for Public Health Actions – A Scoping Review Study](#)**

Nandakumar Ravichandran

medRxiv 2024.08.28.24312706; doi: <https://doi.org/10.1101/2024.08.28.24312706> Revision

### **[Rapid Decline of Mpox Antibody Responses Following MVA-BN Vaccination](#)**

Ai-ris Y. Collier, Katherine McMahan, Catherine Jacob-Dolan, Jinyan Liu, Erica N Borducchi, Bernard Moss, Dan H. Barouch

medRxiv 2024.09.10.24313399; doi: <https://doi.org/10.1101/2024.09.10.24313399>

### **[Mpox vaccination uptake in a UK community sample of gay, bisexual, and other men who have sex with men \(GBMSM\) the year following the 2022 Clade IIb mpox outbreak](#)**

Dolores Mullen, Jessica Edney, Dawn Phillips, Ruth Wilkie, David Reid, Catherine M Lowndes, Erna Buitendam, Katy Sinka, Sema Mandal, Catherine H Mercer, John Saunders, Hamish Mohammed, Dana Ogaz

medRxiv 2024.09.09.24313322; doi: <https://doi.org/10.1101/2024.09.09.24313322>

## **Population Genomics of Plasmodium malariae from Four African Countries**

Zachary R. Popkin-Hall, Kelly Carey-Ewend, Farhang Aghakhanian, Eniyu C. Oriero, Misago D. Seth, Melchior M. Kashamuka, Billy Ngasala, Innocent M. Ali, Eric Sompwe Mukomena, Celine I. Mandara, Oksana Kharabara, Rachel Sendor, Alfred Simkin, Alfred Amambua-Ngwa, Antoinette Tshefu, Abebe A. Fola, Deus S. Ishengoma, Jeffrey A. Bailey, Jonathan B. Parr, Jessica T. Lin, Jonathan J. Juliano  
medRxiv 2024.09.07.24313132; doi: <https://doi.org/10.1101/2024.09.07.24313132>

## **OSF Pre-prints**

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7C%20Life%20Sciences>

*[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-]*  
[No new digest content identified]

## **Wellcome Open Research**

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 14 Sep 2024]

*Selected Research*

[No new digest content identified]

\*

\*

\*

\*

## **Think Tanks**

**Brookings** [to 14 Sep 2024]

<http://www.brookings.edu/>

*Research*

**Examining the capabilities and risks of advanced AI systems**

*Artificial Intelligence*

Chinasa T. Okolo

September 10, 2024

:: Chinasa T. Okolo, a Brookings fellow in the Center for Technology Innovation (CTI), recently contributed to the International Scientific Report on the Safety of Advanced AI – Interim Report published by the United Kingdom Department for Science, Innovation, and Technology.

:: The report explores current and potential future AI capabilities, assessment and understanding of general-purpose AI, risks from such systems, and methods for mitigating such risks.

:: The report also underscores the need for broader global cooperation in defining AI risks and developing robust mitigation solutions.

**Center for Global Development** [to 14 Sep 2024]

<https://www.cgdev.org/>

*All Research*

*BRIEFS*

**Diversifying Manufacturing of Health Products: Ideas for the EU**

Janeen Madan Keller et al.

September 12, 2024

COVID-19 laid bare the shortcomings in health product markets that contributed to inequitable access to medical countermeasures like vaccines, treatments, and diagnostics in low- and middle-

income countries. A key challenge is that manufacturing for health products is concentrated in a handful of co...

**Chatham House** [to 14 Sep 2024]

<https://www.chathamhouse.org/>

*Selected Analysis, Comment, Events*

*No new digest content identified.*

**Council on Foreign Relations** [to 14 Sep 2024]

<https://www.cfr.org/media/news-releases>

*New Releases [Selected]*

*No new digest content identified.*

**CSIS** [to 14 Sep 2024]

<https://www.csis.org/>

*Reports [Selected]*

*No new digest content identified.*

**Kaiser Family Foundation** [to 14 Sep 2024]

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

*Newsroom*

*No new digest content identified.*

**McKinsey Global Institute** [to 14 Sep 2024]

<https://www.mckinsey.com/mgi/overview>

*Latest Research*

*No new digest content identified.*

**ODI [Overseas Development Institute]** [to 14 Sep 2024]

<https://odi.org/en/publications/>

*Publications [Selected]*

*No new digest content identified.*

**Pew Research Center** [to 14 Sep 2024]

<https://www.pewresearch.org/>

*Latest Publications [Selected]*

*No new digest content identified.*

**Rand** [to 14 Sep 2024]

<https://www.rand.org/pubs.html>

*Published Research [Selected]*

**[The Future of International Scientific Assessments of AI's Risks](#)**

Sep 13, 2024

Managing risks from AI will require international coordination among many actors. This report considers ways stakeholders can promote scientific consensus about AI risks by building on efforts begun at the 2023 AI Safety Summit.

**Urban Institute** [to 14 Sep 2024]  
<https://www.urban.org/publications>  
[New Research Publications - Selected](#)

*Research Report*  
[Immigration Enforcement and COVID-19 Death Disparities among Latinx People](#)  
September 13, 2024

**World Economic Forum** [to 14 Sep 2024]  
<https://agenda.weforum.org/press/>  
*Media [Selected]*  
*No new digest content identified.*

.....  
.....

**Public Consultations/Call for Inputs/Call for Papers**

[Call for Public Comment: General Principles on Plan, Design, and Analysis of Pharmacoepidemiological Studies that Utilize Real-World Data for Safety Assessment of Medicines.](#)

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use]

The guideline will focus on non-interventional pharmacoepidemiological studies using Real-World Data (RWD) and will include basic principles that may apply to these studies when real-world data elements are included.

*Public consultation dates [announced to date]:*

- ANVISA, Brazil - Deadline for comments by 24 August 2024
- FDA, United States - Deadline for comments by 3 September 2024
- MFDS, Republic of Korea - Deadline for comments by 15 July 2024
- MHLW/PMDA, Japan - Deadline for comments by 28 July 2024
- NMPA, China - Deadline for comments by 12 October 2024
- TFDA, Chinese Taipei - Deadline for comments by 30 September 2024

*	*	*	*
*	*	*	*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy ([CVEP](#)) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

*Copyright GE2P2 Global Foundation 2024. Some Rights Reserved.*



*This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.*

*Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.*

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*	*	*	*
*	*	*	*